{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:42:43Z","timestamp":1793814163904,"version":"4.6.1"},"reference-count":323,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M742488"],"award-info":[{"award-number":["2023M742488"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Sichuan Science and Technology Program","award":["24NSFSC6690"],"award-info":[{"award-number":["24NSFSC6690"]}]},{"name":"the Sichuan Science and Technology Program","award":["2025ZNSFSC0047"],"award-info":[{"award-number":["2025ZNSFSC0047"]}]},{"name":"\"From 0 to 1\" innovative research project of Sichuan University","award":["2023SCUH0031"],"award-info":[{"award-number":["2023SCUH0031"]}],"id":[{"id":"https:\/\/ror.org\/011ashp19","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Post-Doctor Research Project, West China Hospital, Sichuan University","award":["2023HXBH004"],"award-info":[{"award-number":["2023HXBH004"]}],"id":[{"id":"https:\/\/ror.org\/011ashp19","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82470188"],"award-info":[{"award-number":["82470188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["T2221004"],"award-info":[{"award-number":["T2221004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the 1.3.5. Project for Disciplines of Excellence, West China Hospital, Sichuan University","award":["ZYGD22012"],"award-info":[{"award-number":["ZYGD22012"]}],"id":[{"id":"https:\/\/ror.org\/011ashp19","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the National Science and Technology Major Project of China","award":["2024YFF0507400"],"award-info":[{"award-number":["2024YFF0507400"]}]},{"name":"the Frontiers Medical Center, Tianfu Jincheng Laboratory Foundation","award":["TFJC2023010004"],"award-info":[{"award-number":["TFJC2023010004"]}],"id":[{"id":"https:\/\/ror.org\/00xhkbc10","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University","award":["Z2024JC001"],"award-info":[{"award-number":["Z2024JC001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01690-6","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:22:19Z","timestamp":1743484939000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Current and future therapies for small cell lung carcinoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Xiaoqian","family":"Zhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengkun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmou","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"1690_CR1","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3322\/caac.21785","volume":"73","author":"Z Megyesfalvi","year":"2023","unstructured":"Megyesfalvi Z, et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA A Cancer J Clin. 2023;73:620\u201352. https:\/\/doi.org\/10.3322\/caac.21785.","journal-title":"CA A Cancer J Clin"},{"key":"1690_CR2","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.7150\/jca.75622","volume":"13","author":"B Oronsky","year":"2022","unstructured":"Oronsky B, et al. A 2022 update on extensive stage small-cell lung cancer (SCLC). J Cancer. 2022;13:2945\u201353. https:\/\/doi.org\/10.7150\/jca.75622.","journal-title":"J Cancer"},{"key":"1690_CR3","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nrc.2017.87","volume":"17","author":"AF Gazdar","year":"2017","unstructured":"Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17:725\u201337. https:\/\/doi.org\/10.1038\/nrc.2017.87.","journal-title":"Nat Rev Cancer"},{"key":"1690_CR4","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","volume":"7","author":"S Wang","year":"2017","unstructured":"Wang S, et al. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. Sci Rep. 2017;7:1339. https:\/\/doi.org\/10.1038\/s41598-017-01571-0.","journal-title":"Sci Rep"},{"key":"1690_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100059","volume":"6","author":"M Torres-Dur\u00e1n","year":"2021","unstructured":"Torres-Dur\u00e1n M, et al. Small-cell lung cancer in never-smokers. ESMO Open. 2021;6: 100059. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100059.","journal-title":"ESMO Open"},{"key":"1690_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40265-019-01240-8","volume":"80","author":"N Reguart","year":"2020","unstructured":"Reguart N, Marin E, Remon J, Reyes R, Teixido C. In search of the long-desired \u201ccopernican therapeutic revolution\u201d in small-cell lung cancer. Drugs. 2020;80:241\u201362. https:\/\/doi.org\/10.1007\/s40265-019-01240-8.","journal-title":"Drugs"},{"key":"1690_CR7","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, et al. First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1809064.","journal-title":"N Engl J Med"},{"key":"1690_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.6004\/jnccn.2006.0052","volume":"4","author":"L Gandhi","year":"2006","unstructured":"Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw. 2006;4:631\u20138. https:\/\/doi.org\/10.6004\/jnccn.2006.0052.","journal-title":"J Natl Compr Canc Netw"},{"key":"1690_CR9","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.50616","author":"D Yang","year":"2019","unstructured":"Yang D, et al. Axon-like protrusions promote small cell lung cancer migration and metastasis. Elife. 2019. https:\/\/doi.org\/10.7554\/eLife.50616.","journal-title":"Elife"},{"key":"1690_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/path.1700290304","volume":"29","author":"WG Barnard","year":"1926","unstructured":"Barnard WG. The nature of the \u201coat-celled sarcoma\u201d of the mediastinum. J Pathol Bacteriol. 1926;29:241\u20134. https:\/\/doi.org\/10.1002\/path.1700290304.","journal-title":"J Pathol Bacteriol"},{"key":"1690_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/path.1700780218","volume":"78","author":"JG Azzopardi","year":"1959","unstructured":"Azzopardi JG. Oat-cell carcinoma of the bronchus. J Pathol Bacteriol. 1959;78:513\u20139. https:\/\/doi.org\/10.1002\/path.1700780218.","journal-title":"J Pathol Bacteriol"},{"key":"1690_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7:3. https:\/\/doi.org\/10.1038\/s41572-020-00235-0.","journal-title":"Nat Rev Dis Primers"},{"key":"1690_CR13","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3390\/cancers13040820","volume":"13","author":"MG Raso","year":"2021","unstructured":"Raso MG, Bota-Rabassedas N, Wistuba II. Pathology and classification of SCLC. Cancers. 2021;13:820. https:\/\/doi.org\/10.3390\/cancers13040820.","journal-title":"Cancers"},{"key":"1690_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George J, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47\u201353. https:\/\/doi.org\/10.1038\/nature14664.","journal-title":"Nature"},{"key":"1690_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41392-022-01013-y","volume":"7","author":"M Yuan","year":"2022","unstructured":"Yuan M, et al. Signal pathways and precision therapy of small-cell lung cancer. Signal Transduct Target Ther. 2022;7:187. https:\/\/doi.org\/10.1038\/s41392-022-01013-y.","journal-title":"Signal Transduct Target Ther"},{"key":"1690_CR16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346-360.e347. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.014.","journal-title":"Cancer Cell"},{"key":"1690_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. 2019;19:289\u201397. https:\/\/doi.org\/10.1038\/s41568-019-0133-9.","journal-title":"Nat Rev Cancer"},{"key":"1690_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2022.09.005","volume":"86","author":"T Li","year":"2022","unstructured":"Li T, Qiao T. Unraveling tumor microenvironment of small-cell lung cancer: implications for immunotherapy. Semin Cancer Biol. 2022;86:117\u201325. https:\/\/doi.org\/10.1016\/j.semcancer.2022.09.005.","journal-title":"Semin Cancer Biol"},{"key":"1690_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cllc.2011.03.002","volume":"12","author":"S Haddadin","year":"2011","unstructured":"Haddadin S, Perry MC. History of small-cell lung cancer. Clin Lung Cancer. 2011;12:87\u201393. https:\/\/doi.org\/10.1016\/j.cllc.2011.03.002.","journal-title":"Clin Lung Cancer"},{"key":"1690_CR20","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.ccell.2023.08.007","volume":"41","author":"Z Megyesfalvi","year":"2023","unstructured":"Megyesfalvi Z, et al. Unfolding the secrets of small cell lung cancer progression: novel approaches and insights through rapid autopsies. Cancer Cell. 2023;41:1535\u201340. https:\/\/doi.org\/10.1016\/j.ccell.2023.08.007.","journal-title":"Cancer Cell"},{"key":"1690_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","volume":"12","author":"DH Owen","year":"2019","unstructured":"Owen DH, et al. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019;12:61. https:\/\/doi.org\/10.1186\/s13045-019-0745-2.","journal-title":"J Hematol Oncol"},{"key":"1690_CR22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/sj.bjc.6690745","volume":"81","author":"L Drivsholm","year":"1999","unstructured":"Drivsholm L, Paloheimo LI, Osterlind K. Chromogranin A, a significant prognostic factor in small cell lung cancer. Br J Cancer. 1999;81:667\u201371. https:\/\/doi.org\/10.1038\/sj.bjc.6690745.","journal-title":"Br J Cancer"},{"key":"1690_CR23","first-page":"6068","volume":"50","author":"SM Jensen","year":"1990","unstructured":"Jensen SM, Gazdar AF, Cuttitta F, Russell EK, Linnoila RI. A comparison of synaptophysin, chromogranin, and L-dopa decarboxylase as markers for neuroendocrine differentiation in lung cancer cell lines. Can Res. 1990;50:6068\u201374.","journal-title":"Can Res"},{"key":"1690_CR24","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1101\/gad.263145.115","volume":"29","author":"EA Semenova","year":"2015","unstructured":"Semenova EA, Nagel R, Berns A. Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev. 2015;29:1447\u201362. https:\/\/doi.org\/10.1101\/gad.263145.115.","journal-title":"Genes Dev"},{"key":"1690_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cell.2019.09.010","volume":"179","author":"Y Ouadah","year":"2019","unstructured":"Ouadah Y, et al. Rare pulmonary neuroendocrine cells are stem cells regulated by Rb, p53, and Notch. Cell. 2019;179:403-416.e423. https:\/\/doi.org\/10.1016\/j.cell.2019.09.010.","journal-title":"Cell"},{"key":"1690_CR26","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1084\/jem.20181155","volume":"216","author":"HJ Chen","year":"2019","unstructured":"Chen HJ, et al. Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells. J Exp Med. 2019;216:674\u201387. https:\/\/doi.org\/10.1084\/jem.20181155.","journal-title":"J Exp Med"},{"key":"1690_CR27","doi-asserted-by":"publisher","unstructured":"Chen HJ, Gardner EE, Shah Y, Zhang K, Thakur A, Zhang C, Elemento O, Varmus H. Formation of malignant, metastatic small cell lung cancers through overproduction of cMYC protein in TP53 and RB1 depleted pulmonary neuroendocrine cells derived from human embryonic stem cells. bioRxiv. 2024:2023-10. https:\/\/doi.org\/10.1101\/2023.10.06.561244.","DOI":"10.1101\/2023.10.06.561244"},{"key":"1690_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41388-021-02070-3","volume":"41","author":"J Chen","year":"2022","unstructured":"Chen J, et al. Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium. Oncogene. 2022;41:138\u201345. https:\/\/doi.org\/10.1038\/s41388-021-02070-3.","journal-title":"Oncogene"},{"key":"1690_CR29","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1016\/j.celrep.2020.02.052","volume":"30","author":"G Ferone","year":"2020","unstructured":"Ferone G, et al. FGFR1 oncogenic activation reveals an alternative cell of origin of SCLC in Rb1\/p53 mice. Cell Rep. 2020;30:3837-3850.e3833. https:\/\/doi.org\/10.1016\/j.celrep.2020.02.052.","journal-title":"Cell Rep"},{"key":"1690_CR30","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ccr.2011.04.019","volume":"19","author":"KD Sutherland","year":"2011","unstructured":"Sutherland KD, et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell. 2011;19:754\u201364. https:\/\/doi.org\/10.1016\/j.ccr.2011.04.019.","journal-title":"Cancer Cell"},{"key":"1690_CR31","doi-asserted-by":"publisher","first-page":"eadj1415","DOI":"10.1126\/science.adj1415","volume":"383","author":"EE Gardner","year":"2024","unstructured":"Gardner EE, et al. Lineage-specific intolerance to oncogenic drivers restricts histological transformation. Science. 2024;383:eadj1415. https:\/\/doi.org\/10.1126\/science.adj1415.","journal-title":"Science"},{"key":"1690_CR32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.semcancer.2022.03.006","volume":"86","author":"X Yin","year":"2022","unstructured":"Yin X, et al. Small cell lung cancer transformation: from pathogenesis to treatment. Semin Cancer Biol. 2022;86:595\u2013606. https:\/\/doi.org\/10.1016\/j.semcancer.2022.03.006.","journal-title":"Semin Cancer Biol"},{"key":"1690_CR33","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1097\/coc.0000000000000720","volume":"43","author":"G Clamon","year":"2020","unstructured":"Clamon G, Zeitler W, An J, Hejleh TA. Transformational changes between non-small cell and small cell lung cancer-biological and clinical relevance\u2014a review. Am J Clin Oncol. 2020;43:670\u20135. https:\/\/doi.org\/10.1097\/coc.0000000000000720.","journal-title":"Am J Clin Oncol"},{"key":"1690_CR34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1200\/jco.18.01585","volume":"37","author":"N Marcoux","year":"2019","unstructured":"Marcoux N, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol. 2019;37:278\u201385. https:\/\/doi.org\/10.1200\/jco.18.01585.","journal-title":"J Clin Oncol"},{"key":"1690_CR35","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26. https:\/\/doi.org\/10.1126\/scitranslmed.3002003.","journal-title":"Sci Transl Med"},{"key":"1690_CR36","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/jco.2016.71.9096","volume":"35","author":"JK Lee","year":"2017","unstructured":"Lee JK, et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J Clin Oncol. 2017;35:3065\u201374. https:\/\/doi.org\/10.1200\/jco.2016.71.9096.","journal-title":"J Clin Oncol"},{"key":"1690_CR37","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","volume":"14","author":"M Offin","year":"2019","unstructured":"Offin M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol. 2019;14:1784\u201393. https:\/\/doi.org\/10.1016\/j.jtho.2019.06.002.","journal-title":"J Thorac Oncol"},{"key":"1690_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.lungcan.2016.10.012","volume":"102","author":"D Levacq","year":"2016","unstructured":"Levacq D, D\u2019Haene N, de Wind R, Remmelink M, Berghmans T. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: a new mechanism of resistance to ALK inhibitors. Lung Cancer. 2016;102:38\u201341. https:\/\/doi.org\/10.1016\/j.lungcan.2016.10.012.","journal-title":"Lung Cancer"},{"key":"1690_CR39","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/joim.13201","volume":"289","author":"J Sainz de Aja","year":"2021","unstructured":"Sainz de Aja J, Dost AFM, Kim CF. Alveolar progenitor cells and the origin of lung cancer. J Intern Med. 2021;289:629\u201335. https:\/\/doi.org\/10.1111\/joim.13201.","journal-title":"J Intern Med"},{"key":"1690_CR40","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/j.1349-7006.2007.00600.x","volume":"98","author":"T Fukui","year":"2007","unstructured":"Fukui T, et al. Epidermal growth factor receptor mutation status and clinicopathological features of combined small cell carcinoma with adenocarcinoma of the lung. Cancer Sci. 2007;98:1714\u20139. https:\/\/doi.org\/10.1111\/j.1349-7006.2007.00600.x.","journal-title":"Cancer Sci"},{"key":"1690_CR41","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1073\/pnas.95.6.2834","volume":"95","author":"M Kapoor","year":"1998","unstructured":"Kapoor M, Lozano G. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci U S A. 1998;95:2834\u20137. https:\/\/doi.org\/10.1073\/pnas.95.6.2834.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1690_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004885","volume":"11","author":"D Su","year":"2015","unstructured":"Su D, et al. Interactions of chromatin context, binding site sequence content, and sequence evolution in stress-induced p53 occupancy and transactivation. PLoS Genet. 2015;11: e1004885. https:\/\/doi.org\/10.1371\/journal.pgen.1004885.","journal-title":"PLoS Genet"},{"key":"1690_CR43","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1101\/gr.204149.116","volume":"26","author":"A Verfaillie","year":"2016","unstructured":"Verfaillie A, et al. Multiplex enhancer-reporter assays uncover unsophisticated TP53 enhancer logic. Genome Res. 2016;26:882\u201395. https:\/\/doi.org\/10.1101\/gr.204149.116.","journal-title":"Genome Res"},{"key":"1690_CR44","doi-asserted-by":"publisher","first-page":"16286","DOI":"10.1074\/jbc.M110.108167","volume":"285","author":"JR Burke","year":"2010","unstructured":"Burke JR, Deshong AJ, Pelton JG, Rubin SM. Phosphorylation-induced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding. J Biol Chem. 2010;285:16286\u201393. https:\/\/doi.org\/10.1074\/jbc.M110.108167.","journal-title":"J Biol Chem"},{"key":"1690_CR45","first-page":"1695","volume":"52","author":"CW Miller","year":"1992","unstructured":"Miller CW, et al. p53 mutations in human lung tumors. Can Res. 1992;52:1695\u20138.","journal-title":"Can Res"},{"key":"1690_CR46","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1038\/s41467-023-40161-9","volume":"14","author":"J Acosta","year":"2023","unstructured":"Acosta J, et al. p53 restoration in small cell lung cancer identifies a latent cyclophilin-dependent necrosis mechanism. Nat Commun. 2023;14:4403. https:\/\/doi.org\/10.1038\/s41467-023-40161-9.","journal-title":"Nat Commun"},{"key":"1690_CR47","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3892\/or.2019.7439","volume":"43","author":"X Tang","year":"2020","unstructured":"Tang X, et al. Sirtuin 3 induces apoptosis and necroptosis by regulating mutant p53 expression in small-cell lung cancer. Oncol Rep. 2020;43:591\u2013600. https:\/\/doi.org\/10.3892\/or.2019.7439.","journal-title":"Oncol Rep"},{"key":"1690_CR48","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.1038\/s41467-023-41585-z","volume":"14","author":"Z Wu","year":"2023","unstructured":"Wu Z, et al. YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasis. Nat Commun. 2023;14:5916. https:\/\/doi.org\/10.1038\/s41467-023-41585-z.","journal-title":"Nat Commun"},{"key":"1690_CR49","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/s1535-6108(03)00220-4","volume":"4","author":"R Meuwissen","year":"2003","unstructured":"Meuwissen R, et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell. 2003;4:181\u20139. https:\/\/doi.org\/10.1016\/s1535-6108(03)00220-4.","journal-title":"Cancer Cell"},{"key":"1690_CR50","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1158\/0008-5472.can-09-4228","volume":"70","author":"BE Schaffer","year":"2010","unstructured":"Schaffer BE, et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Can Res. 2010;70:3877\u201383. https:\/\/doi.org\/10.1158\/0008-5472.can-09-4228.","journal-title":"Can Res"},{"key":"1690_CR51","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.cels.2018.03.003","volume":"6","author":"FX Schaub","year":"2018","unstructured":"Schaub FX, et al. Pan-cancer alterations of the MYC oncogene and its proximal network across the cancer genome atlas. Cell Syst. 2018;6:282-300.e282. https:\/\/doi.org\/10.1016\/j.cels.2018.03.003.","journal-title":"Cell Syst"},{"key":"1690_CR52","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/2159-8290.Cd-22-0796","volume":"13","author":"LS Pongor","year":"2023","unstructured":"Pongor LS, et al. Extrachromosomal DNA amplification contributes to small cell lung cancer heterogeneity and is associated with worse outcomes. Cancer Discov. 2023;13:928\u201349. https:\/\/doi.org\/10.1158\/2159-8290.Cd-22-0796.","journal-title":"Cancer Discov"},{"key":"1690_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc2578","author":"AS Patel","year":"2021","unstructured":"Patel AS, et al. Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer. Sci Adv. 2021. https:\/\/doi.org\/10.1126\/sciadv.abc2578.","journal-title":"Sci Adv"},{"key":"1690_CR54","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1200\/jco.2005.11.078","volume":"23","author":"D Williamson","year":"2005","unstructured":"Williamson D, et al. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol. 2005;23:880\u20138. https:\/\/doi.org\/10.1200\/jco.2005.11.078.","journal-title":"J Clin Oncol"},{"key":"1690_CR55","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1101\/gad.340133.120","volume":"34","author":"E Grunblatt","year":"2020","unstructured":"Grunblatt E, et al. MYCN drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity. Genes Dev. 2020;34:1210\u201326. https:\/\/doi.org\/10.1101\/gad.340133.120.","journal-title":"Genes Dev"},{"key":"1690_CR56","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1038\/s41467-021-24164-y","volume":"12","author":"N Roper","year":"2021","unstructured":"Roper N, et al. Notch signaling and efficacy of PD-1\/PD-L1 blockade in relapsed small cell lung cancer. Nat Commun. 2021;12:3880. https:\/\/doi.org\/10.1038\/s41467-021-24164-y.","journal-title":"Nat Commun"},{"key":"1690_CR57","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature22323","volume":"545","author":"JS Lim","year":"2017","unstructured":"Lim JS, et al. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature. 2017;545:360\u20134. https:\/\/doi.org\/10.1038\/nature22323.","journal-title":"Nature"},{"key":"1690_CR58","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1083\/jcb.200503113","volume":"170","author":"E Ladi","year":"2005","unstructured":"Ladi E, et al. The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J Cell Biol. 2005;170:983\u201392. https:\/\/doi.org\/10.1083\/jcb.200503113.","journal-title":"J Cell Biol"},{"key":"1690_CR59","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1111\/cas.13997","volume":"110","author":"M Furuta","year":"2019","unstructured":"Furuta M, et al. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail. Cancer Sci. 2019;110:1599\u2013608. https:\/\/doi.org\/10.1111\/cas.13997.","journal-title":"Cancer Sci"},{"key":"1690_CR60","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","volume":"7","author":"LR Saunders","year":"2015","unstructured":"Saunders LR, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7:302ra136. https:\/\/doi.org\/10.1126\/scitranslmed.aac9459.","journal-title":"Sci Transl Med"},{"key":"1690_CR61","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1097\/jto.0000000000000250","volume":"9","author":"S Umemura","year":"2014","unstructured":"Umemura S, et al. Therapeutic priority of the PI3K\/AKT\/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol. 2014;9:1324\u201331. https:\/\/doi.org\/10.1097\/jto.0000000000000250.","journal-title":"J Thorac Oncol"},{"key":"1690_CR62","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jgg.2021.04.001","volume":"48","author":"X Li","year":"2021","unstructured":"Li X, et al. PI3K\/Akt\/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer. J Genet Genomics. 2021;48:640\u201351. https:\/\/doi.org\/10.1016\/j.jgg.2021.04.001.","journal-title":"J Genet Genomics"},{"key":"1690_CR63","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.jtho.2020.05.026","volume":"15","author":"JA Kern","year":"2020","unstructured":"Kern JA, et al. Role of mTOR As an essential kinase in SCLC. J Thorac Oncol. 2020;15:1522\u201334. https:\/\/doi.org\/10.1016\/j.jtho.2020.05.026.","journal-title":"J Thorac Oncol"},{"key":"1690_CR64","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/cas.13078","volume":"107","author":"M Horie","year":"2016","unstructured":"Horie M, Saito A, Ohshima M, Suzuki HI, Nagase T. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer. Cancer Sci. 2016;107:1755\u201366. https:\/\/doi.org\/10.1111\/cas.13078.","journal-title":"Cancer Sci"},{"key":"1690_CR65","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jgg.2021.12.005","volume":"49","author":"G Mao","year":"2022","unstructured":"Mao G, et al. DRBin: metagenomic binning based on deep representation learning. J Genet Genomics. 2022;49:681\u20134. https:\/\/doi.org\/10.1016\/j.jgg.2021.12.005.","journal-title":"J Genet Genomics"},{"key":"1690_CR66","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"YT Liu","year":"2021","unstructured":"Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11:5365\u201386. https:\/\/doi.org\/10.7150\/thno.58390.","journal-title":"Theranostics"},{"key":"1690_CR67","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/cdd.2008.17","volume":"15","author":"SA Patel","year":"2008","unstructured":"Patel SA, Simon MC. Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ. 2008;15:628\u201334. https:\/\/doi.org\/10.1038\/cdd.2008.17.","journal-title":"Cell Death Differ"},{"key":"1690_CR68","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/JTO.0b013e3182417830","volume":"7","author":"GW Lee","year":"2012","unstructured":"Lee GW, et al. Hypoxia-inducible factor-1\u03b1 and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study. J Thorac Oncol. 2012;7:528\u201334. https:\/\/doi.org\/10.1097\/JTO.0b013e3182417830.","journal-title":"J Thorac Oncol"},{"key":"1690_CR69","doi-asserted-by":"publisher","first-page":"785","DOI":"10.7150\/ijms.19512","volume":"14","author":"CS Lin","year":"2017","unstructured":"Lin CS, Liu TC, Lee MT, Yang SF, Tsao TC. Independent prognostic value of hypoxia-inducible factor 1-alpha expression in small cell lung cancer. Int J Med Sci. 2017;14:785\u201390. https:\/\/doi.org\/10.7150\/ijms.19512.","journal-title":"Int J Med Sci"},{"key":"1690_CR70","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.lungcan.2019.06.009","volume":"134","author":"N Kasahara","year":"2019","unstructured":"Kasahara N, et al. Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer. Lung Cancer. 2019;134:180\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2019.06.009.","journal-title":"Lung Cancer"},{"key":"1690_CR71","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/JTO.0b013e3181dc211f","volume":"5","author":"JJ Jacoby","year":"2010","unstructured":"Jacoby JJ, et al. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J Thorac Oncol. 2010;5:940\u20139. https:\/\/doi.org\/10.1097\/JTO.0b013e3181dc211f.","journal-title":"J Thorac Oncol"},{"key":"1690_CR72","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.semcancer.2022.07.003","volume":"86","author":"G Bononi","year":"2022","unstructured":"Bononi G, et al. Historical perspective of tumor glycolysis: a century with Otto Warburg. Semin Cancer Biol. 2022;86:325\u201333. https:\/\/doi.org\/10.1016\/j.semcancer.2022.07.003.","journal-title":"Semin Cancer Biol"},{"key":"1690_CR73","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood-2005-05-1795","volume":"107","author":"E Gottfried","year":"2006","unstructured":"Gottfried E, et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood. 2006;107:2013\u201321. https:\/\/doi.org\/10.1182\/blood-2005-05-1795.","journal-title":"Blood"},{"key":"1690_CR74","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/imr.12846","volume":"295","author":"PJ Siska","year":"2020","unstructured":"Siska PJ, Singer K, Evert K, Renner K, Kreutz M. The immunological Warburg effect: Can a metabolic-tumor-stroma score (MeTS) guide cancer immunotherapy? Immunol Rev. 2020;295:187\u2013202. https:\/\/doi.org\/10.1111\/imr.12846.","journal-title":"Immunol Rev"},{"key":"1690_CR75","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.semcancer.2020.01.009","volume":"65","author":"A Liu","year":"2020","unstructured":"Liu A, Curran MA. Tumor hypermetabolism confers resistance to immunotherapy. Semin Cancer Biol. 2020;65:155\u201363. https:\/\/doi.org\/10.1016\/j.semcancer.2020.01.009.","journal-title":"Semin Cancer Biol"},{"key":"1690_CR76","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.4049\/jimmunol.178.3.1505","volume":"178","author":"C Bouzin","year":"2007","unstructured":"Bouzin C, Brouet A, De Vriese J, Dewever J, Feron O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol. 2007;178:1505\u201311. https:\/\/doi.org\/10.4049\/jimmunol.178.3.1505.","journal-title":"J Immunol"},{"key":"1690_CR77","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3349\/ymj.2022.63.3.229","volume":"63","author":"Y Sun","year":"2022","unstructured":"Sun Y, et al. MEG3 LncRNA from exosomes released from cancer-associated fibroblasts enhances cisplatin chemoresistance in SCLC via a MiR-15a-5p\/CCNE1 Axis. Yonsei Med J. 2022;63:229\u201340. https:\/\/doi.org\/10.3349\/ymj.2022.63.3.229.","journal-title":"Yonsei Med J"},{"key":"1690_CR78","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1038\/s41598-024-52687-z","volume":"14","author":"Y Lu","year":"2024","unstructured":"Lu Y, et al. Dynamic phenotypic reprogramming and chemoresistance induced by lung fibroblasts in small cell lung cancer. Sci Rep. 2024;14:2884. https:\/\/doi.org\/10.1038\/s41598-024-52687-z.","journal-title":"Sci Rep"},{"key":"1690_CR79","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41392-022-01150-4","volume":"7","author":"Y Tian","year":"2022","unstructured":"Tian Y, et al. Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer. Signal Transduct Target Ther. 2022;7:346. https:\/\/doi.org\/10.1038\/s41392-022-01150-4.","journal-title":"Signal Transduct Target Ther"},{"key":"1690_CR80","doi-asserted-by":"publisher","first-page":"9531","DOI":"10.18632\/oncotarget.3371","volume":"6","author":"A Takahashi","year":"2015","unstructured":"Takahashi A, et al. Podoplanin-expressing cancer-associated fibroblasts inhibit small cell lung cancer growth. Oncotarget. 2015;6:9531\u201341. https:\/\/doi.org\/10.18632\/oncotarget.3371.","journal-title":"Oncotarget"},{"key":"1690_CR81","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/1878-0261.12741","volume":"14","author":"D Dora","year":"2020","unstructured":"Dora D, et al. Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution. Mol Oncol. 2020;14:1947\u201365. https:\/\/doi.org\/10.1002\/1878-0261.12741.","journal-title":"Mol Oncol"},{"key":"1690_CR82","doi-asserted-by":"publisher","first-page":"748","DOI":"10.21037\/tlcr.2019.10.09","volume":"8","author":"Y Sun","year":"2019","unstructured":"Sun Y, et al. Characterization of PD-L1 protein expression and CD8(+) tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer. Transl Lung Cancer Res. 2019;8:748\u201359. https:\/\/doi.org\/10.21037\/tlcr.2019.10.09.","journal-title":"Transl Lung Cancer Res"},{"key":"1690_CR83","doi-asserted-by":"publisher","first-page":"32","DOI":"10.21037\/tlcr.2018.02.02","volume":"7","author":"W Zhang","year":"2018","unstructured":"Zhang W, et al. Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res. 2018;7:32\u201349. https:\/\/doi.org\/10.21037\/tlcr.2018.02.02.","journal-title":"Transl Lung Cancer Res"},{"key":"1690_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102606","volume":"120","author":"Y Chen","year":"2023","unstructured":"Chen Y, Li H, Fan Y. Shaping the tumor immune microenvironment of SCLC: mechanisms, and opportunities for immunotherapy. Cancer Treat Rev. 2023;120: 102606. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102606.","journal-title":"Cancer Treat Rev"},{"key":"1690_CR85","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr ML, et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell. 2019;36:385-401.e388. https:\/\/doi.org\/10.1016\/j.ccell.2019.08.008.","journal-title":"Cancer Cell"},{"key":"1690_CR86","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jtho.2022.05.014","volume":"17","author":"EM Nguyen","year":"2022","unstructured":"Nguyen EM, et al. Targeting lysine-specific demethylase 1 rescues major histocompatibility complex class I antigen presentation and overcomes programmed death-ligand 1 blockade resistance in SCLC. J Thorac Oncol. 2022;17:1014\u201331. https:\/\/doi.org\/10.1016\/j.jtho.2022.05.014.","journal-title":"J Thorac Oncol"},{"key":"1690_CR87","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/s0002-9440(10)64181-8","volume":"161","author":"T Yazawa","year":"2002","unstructured":"Yazawa T, et al. Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma. Am J Pathol. 2002;161:291\u2013300. https:\/\/doi.org\/10.1016\/s0002-9440(10)64181-8.","journal-title":"Am J Pathol"},{"key":"1690_CR88","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.lungcan.2017.07.030","volume":"112","author":"Y He","year":"2017","unstructured":"He Y, et al. MHC class II expression in lung cancer. Lung Cancer. 2017;112:75\u201380. https:\/\/doi.org\/10.1016\/j.lungcan.2017.07.030.","journal-title":"Lung Cancer"},{"key":"1690_CR89","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1158\/1078-0432.Ccr-22-1128","volume":"28","author":"JB Hiatt","year":"2022","unstructured":"Hiatt JB, et al. Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T-cell killing. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28:4551\u201364. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-1128.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1690_CR90","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41467-024-44861-8","volume":"15","author":"B Eglenen-Polat","year":"2024","unstructured":"Eglenen-Polat B, et al. A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer. Nat Commun. 2024;15:672. https:\/\/doi.org\/10.1038\/s41467-024-44861-8.","journal-title":"Nat Commun"},{"key":"1690_CR91","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s42003-021-01842-7","volume":"4","author":"L Cai","year":"2021","unstructured":"Cai L, et al. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer. Commun Biol. 2021;4:314. https:\/\/doi.org\/10.1038\/s42003-021-01842-7.","journal-title":"Commun Biol"},{"key":"1690_CR92","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-0843-1","volume":"13","author":"Z Yang","year":"2020","unstructured":"Yang Z, et al. Myeloid-derived suppressor cells-new and exciting players in lung cancer. J Hematol Oncol. 2020;13:10. https:\/\/doi.org\/10.1186\/s13045-020-0843-1.","journal-title":"J Hematol Oncol"},{"key":"1690_CR93","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3233\/cbm-150473","volume":"15","author":"T Tian","year":"2015","unstructured":"Tian T, et al. Increased circulating CD14(+)HLA-DR-\/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer. Cancer Biomark. 2015;15:425\u201332. https:\/\/doi.org\/10.3233\/cbm-150473.","journal-title":"Cancer Biomark"},{"key":"1690_CR94","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.1016\/j.cllc.2020.10.018","volume":"22","author":"DH Owen","year":"2021","unstructured":"Owen DH, et al. Deep and durable response to nivolumab and temozolomide in small-cell lung cancer associated with an early decrease in myeloid-derived suppressor cells. Clin Lung Cancer. 2021;22:e487\u201397. https:\/\/doi.org\/10.1016\/j.cllc.2020.10.018.","journal-title":"Clin Lung Cancer"},{"key":"1690_CR95","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00262-013-1396-8","volume":"62","author":"C Iclozan","year":"2013","unstructured":"Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother. 2013;62:909\u201318. https:\/\/doi.org\/10.1007\/s00262-013-1396-8.","journal-title":"Cancer Immunol Immunother"},{"key":"1690_CR96","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.21037\/apm-20-1675","volume":"10","author":"X Ying","year":"2021","unstructured":"Ying X, et al. Research progress on the molecular mechanisms of hepatic metastasis in lung cancer: a narrative review. Ann Palliat Med. 2021;10:4806\u201322. https:\/\/doi.org\/10.21037\/apm-20-1675.","journal-title":"Ann Palliat Med"},{"key":"1690_CR97","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3892\/ol.2012.792","volume":"4","author":"K Nakazawa","year":"2012","unstructured":"Nakazawa K, et al. Specific organ metastases and survival in small cell lung cancer. Oncol Lett. 2012;4:617\u201320. https:\/\/doi.org\/10.3892\/ol.2012.792.","journal-title":"Oncol Lett"},{"key":"1690_CR98","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki M, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86:78\u201384. https:\/\/doi.org\/10.1016\/j.lungcan.2014.07.020.","journal-title":"Lung Cancer"},{"key":"1690_CR99","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/pap.0000000000000219","volume":"26","author":"M Akhtar","year":"2019","unstructured":"Akhtar M, Haider A, Rashid S, Al-Nabet A. Paget\u2019s, \u201cseed and soil\u201d theory of cancer metastasis: an idea whose time has come. Adv Anat Pathol. 2019;26:69\u201374. https:\/\/doi.org\/10.1097\/pap.0000000000000219.","journal-title":"Adv Anat Pathol"},{"key":"1690_CR100","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013122","volume":"13","author":"J Ko","year":"2021","unstructured":"Ko J, Winslow MM, Sage J. Mechanisms of small cell lung cancer metastasis. EMBO Mol Med. 2021;13: e13122. https:\/\/doi.org\/10.15252\/emmm.202013122.","journal-title":"EMBO Mol Med"},{"key":"1690_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100265","volume":"19","author":"L Gong","year":"2019","unstructured":"Gong L, et al. Clinical outcome for small cell lung cancer patients with bone metastases at the time of diagnosis. J Bone Oncol. 2019;19: 100265. https:\/\/doi.org\/10.1016\/j.jbo.2019.100265.","journal-title":"J Bone Oncol"},{"key":"1690_CR102","doi-asserted-by":"publisher","first-page":"1097897","DOI":"10.3389\/fonc.2023.1097897","volume":"13","author":"Q Chen","year":"2023","unstructured":"Chen Q, et al. Deep learning of bone metastasis in small cell lung cancer: a large sample-based study. Front Oncol. 2023;13:1097897. https:\/\/doi.org\/10.3389\/fonc.2023.1097897.","journal-title":"Front Oncol"},{"key":"1690_CR103","doi-asserted-by":"publisher","first-page":"9561","DOI":"10.18632\/aging.205035","volume":"15","author":"Y Lin","year":"2023","unstructured":"Lin Y, Jiang W, Su CY, Pan XB. Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis. Aging. 2023;15:9561\u201371. https:\/\/doi.org\/10.18632\/aging.205035.","journal-title":"Aging"},{"key":"1690_CR104","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3892\/ol.2020.12402","volume":"21","author":"P Chen","year":"2021","unstructured":"Chen P, et al. Annexin A1 is a potential biomarker of bone metastasis in small cell lung cancer. Oncol Lett. 2021;21:141. https:\/\/doi.org\/10.3892\/ol.2020.12402.","journal-title":"Oncol Lett"},{"key":"1690_CR105","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13578-023-01112-5","volume":"13","author":"S Li","year":"2023","unstructured":"Li S, et al. Comparative proteomic profiling of plasma exosomes in lung cancer cases of liver and brain metastasis. Cell Biosci. 2023;13:180. https:\/\/doi.org\/10.1186\/s13578-023-01112-5.","journal-title":"Cell Biosci"},{"key":"1690_CR106","doi-asserted-by":"publisher","first-page":"166557","DOI":"10.1016\/j.bbadis.2022.166557","volume":"1868","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Cui Y, Zheng X, Zhao Y, Sun G. Small-cell lung cancer brain metastasis: From molecular mechanisms to diagnosis and treatment. Biochim Biophys acta Mol Basis Dis. 2022;1868:166557. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166557.","journal-title":"Biochim Biophys acta Mol Basis Dis"},{"key":"1690_CR107","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s12035-021-02600-w","volume":"59","author":"GA Sarkis","year":"2022","unstructured":"Sarkis GA, et al. Generation and release of Neurogranin, Vimentin, and MBP proteolytic peptides, following traumatic brain injury. Mol Neurobiol. 2022;59:731\u201347. https:\/\/doi.org\/10.1007\/s12035-021-02600-w.","journal-title":"Mol Neurobiol"},{"key":"1690_CR108","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","volume":"31","author":"G Mollaoglu","year":"2017","unstructured":"Mollaoglu G, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. Cancer Cell. 2017;31:270\u201385. https:\/\/doi.org\/10.1016\/j.ccell.2016.12.005.","journal-title":"Cancer Cell"},{"key":"1690_CR109","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/1541-7786.mcr-13-0554","volume":"12","author":"M Cui","year":"2014","unstructured":"Cui M, et al. PTEN is a potent suppressor of small cell lung cancer. Mol Cancer Res MCR. 2014;12:654\u20139. https:\/\/doi.org\/10.1158\/1541-7786.mcr-13-0554.","journal-title":"Mol Cancer Res MCR"},{"key":"1690_CR110","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/jto.0000000000000459","volume":"10","author":"AF Gazdar","year":"2015","unstructured":"Gazdar AF, et al. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015;10:553\u201364. https:\/\/doi.org\/10.1097\/jto.0000000000000459.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"1690_CR111","doi-asserted-by":"publisher","first-page":"e2207606","DOI":"10.1002\/smll.202207606","volume":"19","author":"X Ji","year":"2023","unstructured":"Ji X, et al. Premetastatic niche mimicking bone-On-A-Chip: a microfluidic platform to study bone metastasis in cancer patients. Small. 2023;19:e2207606. https:\/\/doi.org\/10.1002\/smll.202207606.","journal-title":"Small"},{"key":"1690_CR112","doi-asserted-by":"publisher","first-page":"71223","DOI":"10.18632\/oncotarget.19333","volume":"8","author":"RV Lukas","year":"2017","unstructured":"Lukas RV, Gondi V, Kamson DO, Kumthekar P, Salgia R. State-of-the-art considerations in small cell lung cancer brain metastases. Oncotarget. 2017;8:71223\u201333. https:\/\/doi.org\/10.18632\/oncotarget.19333.","journal-title":"Oncotarget"},{"key":"1690_CR113","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41556-023-01241-6","volume":"25","author":"F Qu","year":"2023","unstructured":"Qu F, et al. Crosstalk between small-cell lung cancer cells and astrocytes mimics brain development to promote brain metastasis. Nat Cell Biol. 2023;25:1506\u201319. https:\/\/doi.org\/10.1038\/s41556-023-01241-6.","journal-title":"Nat Cell Biol"},{"key":"1690_CR114","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s13046-021-02173-5","volume":"40","author":"RY Fan","year":"2021","unstructured":"Fan RY, et al. Zebrafish xenograft model for studying mechanism and treatment of non-small cell lung cancer brain metastasis. J Exp Clin Cancer Res CR. 2021;40:371. https:\/\/doi.org\/10.1186\/s13046-021-02173-5.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"1690_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154613","volume":"109","author":"SR Zhang","year":"2023","unstructured":"Zhang SR, et al. Efficacy and mechanism study of cordycepin against brain metastases of small cell lung cancer based on zebrafish. Phytomed Int J Phytother Phytopharmacol. 2023;109: 154613. https:\/\/doi.org\/10.1016\/j.phymed.2022.154613.","journal-title":"Phytomed Int J Phytother Phytopharmacol"},{"key":"1690_CR116","doi-asserted-by":"publisher","first-page":"E8234","DOI":"10.1073\/pnas.1618389114","volume":"114","author":"R Fior","year":"2017","unstructured":"Fior R, et al. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. Proc Natl Acad Sci USA. 2017;114:E8234-e8243. https:\/\/doi.org\/10.1073\/pnas.1618389114.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1690_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcp.2023.101918","volume":"71","author":"Y Ma","year":"2023","unstructured":"Ma Y, et al. COTE-1 promotes the proliferation and invasion of small cell lung cancer by regulating autophagy activity via the AMPK\/mTOR signaling pathway. Mol Cell Probes. 2023;71: 101918. https:\/\/doi.org\/10.1016\/j.mcp.2023.101918.","journal-title":"Mol Cell Probes"},{"key":"1690_CR118","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.166402","author":"L Meder","year":"2024","unstructured":"Meder L, et al. Blocking the angiopoietin-2-dependent integrin \u03b2-1 signaling axis abrogates small cell lung cancer invasion and metastasis. JCI Insight. 2024. https:\/\/doi.org\/10.1172\/jci.insight.166402.","journal-title":"JCI Insight"},{"key":"1690_CR119","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.ccell.2021.09.008","volume":"39","author":"JM Chan","year":"2021","unstructured":"Chan JM, et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell. 2021;39:1479-1496.e1418. https:\/\/doi.org\/10.1016\/j.ccell.2021.09.008.","journal-title":"Cancer Cell"},{"key":"1690_CR120","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/s41556-024-01446-3","volume":"26","author":"M Seehawer","year":"2024","unstructured":"Seehawer M, et al. Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation of MMP3. Nat Cell Biol. 2024;26:1165\u201375. https:\/\/doi.org\/10.1038\/s41556-024-01446-3.","journal-title":"Nat Cell Biol"},{"key":"1690_CR121","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/cas.15716","volume":"114","author":"R Liu","year":"2023","unstructured":"Liu R, et al. Association of KMT2C\/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer. Cancer Sci. 2023;114:1229\u201339. https:\/\/doi.org\/10.1111\/cas.15716.","journal-title":"Cancer Sci"},{"key":"1690_CR122","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s43018-022-00361-6","volume":"3","author":"F Na","year":"2022","unstructured":"Na F, et al. KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming. Nat Cancer. 2022;3:753\u201367. https:\/\/doi.org\/10.1038\/s43018-022-00361-6.","journal-title":"Nat Cancer"},{"key":"1690_CR123","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1101\/gad.2046711","volume":"25","author":"AL Dooley","year":"2011","unstructured":"Dooley AL, et al. Nuclear factor I\/B is an oncogene in small cell lung cancer. Genes Dev. 2011;25:1470\u20135. https:\/\/doi.org\/10.1101\/gad.2046711.","journal-title":"Genes Dev"},{"key":"1690_CR124","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.cell.2016.05.052","volume":"166","author":"SK Denny","year":"2016","unstructured":"Denny SK, et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility. Cell. 2016;166:328\u201342. https:\/\/doi.org\/10.1016\/j.cell.2016.05.052.","journal-title":"Cell"},{"key":"1690_CR125","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1016\/j.celrep.2019.05.057","volume":"27","author":"F B\u00f6ttger","year":"2019","unstructured":"B\u00f6ttger F, et al. Tumor heterogeneity underlies differential cisplatin sensitivity in mouse models of small-cell lung cancer. Cell Rep. 2019;27:3345-3358.e3344. https:\/\/doi.org\/10.1016\/j.celrep.2019.05.057.","journal-title":"Cell Rep"},{"key":"1690_CR126","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nature14403","volume":"520","author":"E Wagenblast","year":"2015","unstructured":"Wagenblast E, et al. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature. 2015;520:358\u201362. https:\/\/doi.org\/10.1038\/nature14403.","journal-title":"Nature"},{"key":"1690_CR127","doi-asserted-by":"publisher","first-page":"13322","DOI":"10.1038\/ncomms13322","volume":"7","author":"SC Williamson","year":"2016","unstructured":"Williamson SC, et al. Vasculogenic mimicry in small cell lung cancer. Nat Commun. 2016;7:13322. https:\/\/doi.org\/10.1038\/ncomms13322.","journal-title":"Nat Commun"},{"key":"1690_CR128","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41416-022-02103-y","volume":"128","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. Molecular features and evolutionary trajectory of ASCL1(+) and NEUROD1(+) SCLC cells. Br J Cancer. 2023;128:748\u201359. https:\/\/doi.org\/10.1038\/s41416-022-02103-y.","journal-title":"Br J Cancer"},{"key":"1690_CR129","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/s0140-6736(82)91748-2","volume":"1","author":"DN Carney","year":"1982","unstructured":"Carney DN, et al. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer. Lancet (London, England). 1982;1:583\u20135. https:\/\/doi.org\/10.1016\/s0140-6736(82)91748-2.","journal-title":"Lancet (London, England)"},{"key":"1690_CR130","first-page":"37","volume":"19","author":"N van Zandwijk","year":"1992","unstructured":"van Zandwijk N, Jassem E, Bonfrer JM, Mooi WJ, van Tinteren H. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol. 1992;19:37\u201343.","journal-title":"Semin Oncol"},{"key":"1690_CR131","doi-asserted-by":"publisher","first-page":"119451","DOI":"10.1016\/j.bbamcr.2023.119451","volume":"1870","author":"L Li","year":"2023","unstructured":"Li L, et al. CEMIP-mediated hyaluronan metabolism facilitates SCLC metastasis by activating TLR2\/c-Src\/ERK1\/2 axis. Biochim Biophys Acta Mol Cell Res. 2023;1870:119451. https:\/\/doi.org\/10.1016\/j.bbamcr.2023.119451.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"1690_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.1","volume":"46","author":"WY Kim","year":"2014","unstructured":"Kim WY, et al. Syntenin increases the invasiveness of small cell lung cancer cells by activating p38, AKT, focal adhesion kinase and SP1. Exp Mol Med. 2014;46: e90. https:\/\/doi.org\/10.1038\/emm.2014.1.","journal-title":"Exp Mol Med"},{"key":"1690_CR133","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1038\/onc.2011.89","volume":"30","author":"JV Burnier","year":"2011","unstructured":"Burnier JV, et al. Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis. Oncogene. 2011;30:3766\u201383. https:\/\/doi.org\/10.1038\/onc.2011.89.","journal-title":"Oncogene"},{"key":"1690_CR134","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1155\/2001\/870205","volume":"15","author":"K Neubauer","year":"2001","unstructured":"Neubauer K, Saile B, Ramadori G. Liver fibrosis and altered matrix synthesis. Can J Gastroenterol. 2001;15:187\u201393. https:\/\/doi.org\/10.1155\/2001\/870205.","journal-title":"Can J Gastroenterol"},{"key":"1690_CR135","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1053\/gast.2003.50012","volume":"124","author":"C Yang","year":"2003","unstructured":"Yang C, et al. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology. 2003;124:147\u201359. https:\/\/doi.org\/10.1053\/gast.2003.50012.","journal-title":"Gastroenterology"},{"key":"1690_CR136","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/s1359-6446(01)02023-2","volume":"6","author":"M Habeck","year":"2001","unstructured":"Habeck M. Targeting the extracellular matrix to stop tumour progression. Drug Discov Today. 2001;6:1077\u20138. https:\/\/doi.org\/10.1016\/s1359-6446(01)02023-2.","journal-title":"Drug Discov Today"},{"key":"1690_CR137","doi-asserted-by":"publisher","DOI":"10.1172\/jci157917","author":"Y He","year":"2022","unstructured":"He Y, et al. IL-20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer. J Clin Investig. 2022. https:\/\/doi.org\/10.1172\/jci157917.","journal-title":"J Clin Investig"},{"key":"1690_CR138","doi-asserted-by":"publisher","first-page":"1609828","DOI":"10.3389\/pore.2021.1609828","volume":"27","author":"MI Umar","year":"2021","unstructured":"Umar MI, et al. The adipokine component in the molecular regulation of cancer cell survival, proliferation and metastasis. Pathol Oncol Res POR. 2021;27:1609828. https:\/\/doi.org\/10.3389\/pore.2021.1609828.","journal-title":"Pathol Oncol Res POR"},{"key":"1690_CR139","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1158\/2159-8290.cd-17-0987","volume":"8","author":"D Yang","year":"2018","unstructured":"Yang D, et al. Intertumoral heterogeneity in SCLC is influenced by the cell type of origin. Cancer Discov. 2018;8:1316\u201331. https:\/\/doi.org\/10.1158\/2159-8290.cd-17-0987.","journal-title":"Cancer Discov"},{"key":"1690_CR140","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/ng.2405","volume":"44","author":"CM Rudin","year":"2012","unstructured":"Rudin CM, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44:1111\u20136. https:\/\/doi.org\/10.1038\/ng.2405.","journal-title":"Nat Genet"},{"key":"1690_CR141","first-page":"2913","volume":"45","author":"DN Carney","year":"1985","unstructured":"Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Can Res. 1985;45:2913\u201323.","journal-title":"Can Res"},{"key":"1690_CR142","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccell.2024.01.001","volume":"42","author":"S Heeke","year":"2024","unstructured":"Heeke S, et al. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell. 2024;42:225-237.e225. https:\/\/doi.org\/10.1016\/j.ccell.2024.01.001.","journal-title":"Cancer Cell"},{"key":"1690_CR143","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jtho.2024.10.004","volume":"20","author":"S Umemura","year":"2025","unstructured":"Umemura S, et al. Clinical significance of a prospective large genomic screening for SCLC: the genetic classification and a biomarker-driven phase 2 trial of gedatolisib. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2025;20:177\u201393. https:\/\/doi.org\/10.1016\/j.jtho.2024.10.004.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"1690_CR144","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/path.5922","volume":"257","author":"Z Megyesfalvi","year":"2022","unstructured":"Megyesfalvi Z, et al. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. J Pathol. 2022;257:674\u201386. https:\/\/doi.org\/10.1002\/path.5922.","journal-title":"J Pathol"},{"key":"1690_CR145","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1101\/gad.13.13.1647","volume":"13","author":"T Miyata","year":"1999","unstructured":"Miyata T, Maeda T, Lee JE. NeuroD is required for differentiation of the granule cells in the cerebellum and hippocampus. Genes Dev. 1999;13:1647\u201352. https:\/\/doi.org\/10.1101\/gad.13.13.1647.","journal-title":"Genes Dev"},{"key":"1690_CR146","doi-asserted-by":"publisher","first-page":"21160","DOI":"10.1074\/jbc.M708692200","volume":"283","author":"ER Neptune","year":"2008","unstructured":"Neptune ER, et al. Targeted disruption of NeuroD, a proneural basic helix-loop-helix factor, impairs distal lung formation and neuroendocrine morphology in the neonatal lung. J Biol Chem. 2008;283:21160\u20139. https:\/\/doi.org\/10.1074\/jbc.M708692200.","journal-title":"J Biol Chem"},{"key":"1690_CR147","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.lungcan.2020.05.012","volume":"146","author":"Y Ikematsu","year":"2020","unstructured":"Ikematsu Y, et al. NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration. Lung Cancer. 2020;146:97\u2013104. https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.012.","journal-title":"Lung Cancer"},{"key":"1690_CR148","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1091\/mbc.E13-06-0316","volume":"25","author":"JK Osborne","year":"2014","unstructured":"Osborne JK, et al. NeuroD1 mediates nicotine-induced migration and invasion via regulation of the nicotinic acetylcholine receptor subunits in a subset of neural and neuroendocrine carcinomas. Mol Biol Cell. 2014;25:1782\u201392. https:\/\/doi.org\/10.1091\/mbc.E13-06-0316.","journal-title":"Mol Biol Cell"},{"key":"1690_CR149","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jtho.2022.06.004","volume":"17","author":"MK Baine","year":"2022","unstructured":"Baine MK, et al. POU2F3 in SCLC: clinicopathologic and genomic analysis with a focus on its diagnostic utility in neuroendocrine-low SCLC. J Thorac Oncol. 2022;17:1109\u201321. https:\/\/doi.org\/10.1016\/j.jtho.2022.06.004.","journal-title":"J Thorac Oncol"},{"key":"1690_CR150","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189340","volume":"12","author":"J Yamashita","year":"2017","unstructured":"Yamashita J, Ohmoto M, Yamaguchi T, Matsumoto I, Hirota J. Skn-1a\/Pou2f3 functions as a master regulator to generate Trpm5-expressing chemosensory cells in mice. PLoS ONE. 2017;12: e0189340. https:\/\/doi.org\/10.1371\/journal.pone.0189340.","journal-title":"PLoS ONE"},{"key":"1690_CR151","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1101\/gad.314815.118","volume":"32","author":"YH Huang","year":"2018","unstructured":"Huang YH, et al. POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev. 2018;32:915\u201328. https:\/\/doi.org\/10.1101\/gad.314815.118.","journal-title":"Genes Dev"},{"key":"1690_CR152","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","volume":"15","author":"MK Baine","year":"2020","unstructured":"Baine MK, et al. SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2020;15:1823\u201335. https:\/\/doi.org\/10.1016\/j.jtho.2020.09.009.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"1690_CR153","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/s41419-023-06053-y","volume":"14","author":"P Chen","year":"2023","unstructured":"Chen P, et al. YAP1 expression is associated with survival and immunosuppression in small cell lung cancer. Cell Death Dis. 2023;14:636. https:\/\/doi.org\/10.1038\/s41419-023-06053-y.","journal-title":"Cell Death Dis"},{"key":"1690_CR154","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2023.12.004","volume":"187","author":"Q Liu","year":"2024","unstructured":"Liu Q, et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell. 2024;187:184-203.e128. https:\/\/doi.org\/10.1016\/j.cell.2023.12.004.","journal-title":"Cell"},{"key":"1690_CR155","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1158\/1078-0432.Ccr-20-2845","volume":"27","author":"MJ Giffin","year":"2021","unstructured":"Giffin MJ, et al. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27:1526\u201337. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-2845.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1690_CR156","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41556-023-01210-z","volume":"25","author":"L Duplaquet","year":"2023","unstructured":"Duplaquet L, et al. KDM6A epigenetically regulates subtype plasticity in small cell lung cancer. Nat Cell Biol. 2023;25:1346\u201358. https:\/\/doi.org\/10.1038\/s41556-023-01210-z.","journal-title":"Nat Cell Biol"},{"key":"1690_CR157","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","volume":"38","author":"AS Ireland","year":"2020","unstructured":"Ireland AS, et al. MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell. 2020;38:60-78.e12. https:\/\/doi.org\/10.1016\/j.ccell.2020.05.001.","journal-title":"Cancer Cell"},{"key":"1690_CR158","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11060-016-2216-8","volume":"130","author":"AS Berghoff","year":"2016","unstructured":"Berghoff AS, et al. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). J Neurooncol. 2016;130:19\u201329. https:\/\/doi.org\/10.1007\/s11060-016-2216-8.","journal-title":"J Neurooncol"},{"key":"1690_CR159","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1200\/jco.2002.12.111","volume":"20","author":"S Sundstr\u00f8m","year":"2002","unstructured":"Sundstr\u00f8m S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years\u2019 follow-up. J Clin Oncol. 2002;20:4665\u201372. https:\/\/doi.org\/10.1200\/jco.2002.12.111.","journal-title":"J Clin Oncol"},{"key":"1690_CR160","doi-asserted-by":"publisher","first-page":"1142081","DOI":"10.3389\/fonc.2023.1142081","volume":"13","author":"S Zhang","year":"2023","unstructured":"Zhang S, Cheng Y. Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives. Front Oncol. 2023;13:1142081. https:\/\/doi.org\/10.3389\/fonc.2023.1142081.","journal-title":"Front Oncol"},{"key":"1690_CR161","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41586-024-07177-7","volume":"627","author":"J George","year":"2024","unstructured":"George J, et al. Evolutionary trajectories of small cell lung cancer under therapy. Nature. 2024;627:880\u20139. https:\/\/doi.org\/10.1038\/s41586-024-07177-7.","journal-title":"Nature"},{"key":"1690_CR162","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1038\/s41467-018-06162-9","volume":"9","author":"AH Wagner","year":"2018","unstructured":"Wagner AH, et al. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nat Commun. 2018;9:3787. https:\/\/doi.org\/10.1038\/s41467-018-06162-9.","journal-title":"Nat Commun"},{"key":"1690_CR163","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jtho.2019.10.013","volume":"15","author":"TK Owonikoko","year":"2020","unstructured":"Owonikoko TK, et al. Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: primary and correlative biomarker analyses. J Thorac Oncol. 2020;15:274\u201387. https:\/\/doi.org\/10.1016\/j.jtho.2019.10.013.","journal-title":"J Thorac Oncol"},{"key":"1690_CR164","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/08977194.2015.1088533","volume":"33","author":"Z Wang","year":"2015","unstructured":"Wang Z, et al. Increased insulin-like growth factor 1 receptor (IGF1R) expression in small cell lung cancer and the effect of inhibition of IGF1R expression by RNAi on growth of human small cell lung cancer NCI-H446 cell. Growth Factors (Chur, Switzerland). 2015;33:337\u201346. https:\/\/doi.org\/10.3109\/08977194.2015.1088533.","journal-title":"Growth Factors (Chur, Switzerland)"},{"key":"1690_CR165","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.lungcan.2022.11.014","volume":"175","author":"E Caliman","year":"2023","unstructured":"Caliman E, et al. Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification. Lung Cancer. 2023;175:88\u2013100. https:\/\/doi.org\/10.1016\/j.lungcan.2022.11.014.","journal-title":"Lung Cancer"},{"key":"1690_CR166","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1002\/ijc.31561","volume":"143","author":"M Shibata","year":"2018","unstructured":"Shibata M, Ham K, Hoque MO. A time for YAP1: tumorigenesis, immunosuppression and targeted therapy. Int J Cancer. 2018;143:2133\u201344. https:\/\/doi.org\/10.1002\/ijc.31561.","journal-title":"Int J Cancer"},{"key":"1690_CR167","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1158\/2159-8290.cd-23-0225","volume":"13","author":"A Davies","year":"2023","unstructured":"Davies A, Zoubeidi A, Beltran H, Selth LA. The Transcriptional and epigenetic landscape of cancer cell lineage plasticity. Cancer Discov. 2023;13:1771\u201388. https:\/\/doi.org\/10.1158\/2159-8290.cd-23-0225.","journal-title":"Cancer Discov"},{"key":"1690_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100561","volume":"4","author":"YC Lo","year":"2023","unstructured":"Lo YC, Rivera-Concepcion J, Vasmatzis G, Aubry MC, Leventakos K. Subtype of SCLC Is an intrinsic and persistent feature through systemic treatment. JTO Clin Res Rep. 2023;4: 100561. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100561.","journal-title":"JTO Clin Res Rep"},{"key":"1690_CR169","doi-asserted-by":"publisher","first-page":"73745","DOI":"10.18632\/oncotarget.20572","volume":"8","author":"K McColl","year":"2017","unstructured":"McColl K, et al. Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer. Oncotarget. 2017;8:73745\u201356. https:\/\/doi.org\/10.18632\/oncotarget.20572.","journal-title":"Oncotarget"},{"key":"1690_CR170","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-024-01572-3","volume":"17","author":"E Redin","year":"2024","unstructured":"Redin E, et al. SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing. J Hematol Oncol. 2024;17:58. https:\/\/doi.org\/10.1186\/s13045-024-01572-3.","journal-title":"J Hematol Oncol"},{"key":"1690_CR171","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1158\/0008-5472.can-13-1541","volume":"74","author":"S Sarvi","year":"2014","unstructured":"Sarvi S, et al. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Can Res. 2014;74:1554\u201365. https:\/\/doi.org\/10.1158\/0008-5472.can-13-1541.","journal-title":"Can Res"},{"key":"1690_CR172","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","volume":"31","author":"EE Gardner","year":"2017","unstructured":"Gardner EE, et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis. Cancer Cell. 2017;31:286\u201399. https:\/\/doi.org\/10.1016\/j.ccell.2017.01.006.","journal-title":"Cancer Cell"},{"key":"1690_CR173","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1158\/1078-0432.Ccr-18-4140","volume":"25","author":"MD Chalishazar","year":"2019","unstructured":"Chalishazar MD, et al. MYC-driven small-cell lung cancer is metabolically distinct and vulnerable to arginine depletion. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25:5107\u201321. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-4140.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1690_CR174","doi-asserted-by":"publisher","first-page":"8423","DOI":"10.1158\/0008-5472.can-05-0058","volume":"65","author":"J Tsurutani","year":"2005","unstructured":"Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA. Inhibition of the phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin pathway but not the MEK\/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Can Res. 2005;65:8423\u201332. https:\/\/doi.org\/10.1158\/0008-5472.can-05-0058.","journal-title":"Can Res"},{"key":"1690_CR175","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.molcel.2020.10.033","volume":"80","author":"MA Rubin","year":"2020","unstructured":"Rubin MA, Bristow RG, Thienger PD, Dive C, Imielinski M. Impact of lineage plasticity to and from a neuroendocrine phenotype on progression and response in prostate and lung cancers. Mol Cell. 2020;80:562\u201377. https:\/\/doi.org\/10.1016\/j.molcel.2020.10.033.","journal-title":"Mol Cell"},{"key":"1690_CR176","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","volume":"17","author":"Y Pommier","year":"2010","unstructured":"Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17:421\u201333. https:\/\/doi.org\/10.1016\/j.chembiol.2010.04.012.","journal-title":"Chem Biol"},{"key":"1690_CR177","doi-asserted-by":"publisher","first-page":"e2308977","DOI":"10.1002\/adma.202308977","volume":"36","author":"X Zheng","year":"2024","unstructured":"Zheng X, et al. Nanomedicine combats drug resistance in lung cancer. Adv Mater (Deerfield Beach Fla). 2024;36:e2308977. https:\/\/doi.org\/10.1002\/adma.202308977.","journal-title":"Adv Mater (Deerfield Beach Fla)"},{"key":"1690_CR178","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1093\/nar\/gkl468","volume":"34","author":"P Linder","year":"2006","unstructured":"Linder P. Dead-box proteins: a family affair\u2013active and passive players in RNP-remodeling. Nucleic Acids Res. 2006;34:4168\u201380. https:\/\/doi.org\/10.1093\/nar\/gkl468.","journal-title":"Nucleic Acids Res"},{"key":"1690_CR179","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cell.2006.01.054","volume":"125","author":"T Sengoku","year":"2006","unstructured":"Sengoku T, Nureki O, Nakamura A, Kobayashi S, Yokoyama S. Structural basis for RNA unwinding by the DEAD-box protein drosophila vasa. Cell. 2006;125:287\u2013300. https:\/\/doi.org\/10.1016\/j.cell.2006.01.054.","journal-title":"Cell"},{"key":"1690_CR180","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s42003-023-04444-7","volume":"6","author":"C Noyes","year":"2023","unstructured":"Noyes C, et al. The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cells. Commun Biol. 2023;6:65. https:\/\/doi.org\/10.1038\/s42003-023-04444-7.","journal-title":"Commun Biol"},{"key":"1690_CR181","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-genet-021920-092410","volume":"54","author":"B Bonilla","year":"2020","unstructured":"Bonilla B, Hengel SR, Grundy MK, Bernstein KA. RAD51 gene family structure and function. Annu Rev Genet. 2020;54:25\u201346. https:\/\/doi.org\/10.1146\/annurev-genet-021920-092410.","journal-title":"Annu Rev Genet"},{"key":"1690_CR182","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/ng.569","volume":"42","author":"A Meindl","year":"2010","unstructured":"Meindl A, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42:410\u20134. https:\/\/doi.org\/10.1038\/ng.569.","journal-title":"Nat Genet"},{"key":"1690_CR183","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ijc.11106","volume":"105","author":"LT Hansen","year":"2003","unstructured":"Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T. The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer. 2003;105:472\u20139. https:\/\/doi.org\/10.1002\/ijc.11106.","journal-title":"Int J Cancer"},{"key":"1690_CR184","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.freeradbiomed.2022.08.015","volume":"190","author":"P Tripathi","year":"2022","unstructured":"Tripathi P, Soni R, Antra, Tandon V. Pixantrone confers radiosensitization in KRAS mutated cancer cells by suppression of radiation-induced prosurvival pathways. Free Radic Biol Med. 2022;190:351\u201362. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.08.015.","journal-title":"Free Radic Biol Med"},{"key":"1690_CR185","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1038\/s41467-020-15819-3","volume":"11","author":"J Cheng","year":"2020","unstructured":"Cheng J, et al. TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K\/AKT pathway and PPP metabolism. Nat Commun. 2020;11:1880. https:\/\/doi.org\/10.1038\/s41467-020-15819-3.","journal-title":"Nat Commun"},{"key":"1690_CR186","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1158\/1078-0432.ccr-12-0858","volume":"18","author":"TW Meijer","year":"2012","unstructured":"Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:5585\u201394. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-0858.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1690_CR187","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41419-023-06171-7","volume":"14","author":"H Deng","year":"2023","unstructured":"Deng H, et al. PI3K\/mTOR inhibitors promote G6PD autophagic degradation and exacerbate oxidative stress damage to radiosensitize small cell lung cancer. Cell Death Dis. 2023;14:652. https:\/\/doi.org\/10.1038\/s41419-023-06171-7.","journal-title":"Cell Death Dis"},{"key":"1690_CR188","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40170-021-00270-9","volume":"9","author":"KR Cargill","year":"2021","unstructured":"Cargill KR, et al. Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. Cancer Metab. 2021;9:33. https:\/\/doi.org\/10.1186\/s40170-021-00270-9.","journal-title":"Cancer Metab"},{"key":"1690_CR189","doi-asserted-by":"publisher","DOI":"10.1172\/jci139929","author":"F Huang","year":"2021","unstructured":"Huang F, et al. Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer. J Clin Investig. 2021. https:\/\/doi.org\/10.1172\/jci139929.","journal-title":"J Clin Investig"},{"key":"1690_CR190","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1158\/0008-5472.can-17-2109","volume":"78","author":"H Makinoshima","year":"2018","unstructured":"Makinoshima H, et al. Metabolic determinants of sensitivity to phosphatidylinositol 3-kinase pathway inhibitor in small-cell lung carcinoma. Can Res. 2018;78:2179\u201390. https:\/\/doi.org\/10.1158\/0008-5472.can-17-2109.","journal-title":"Can Res"},{"key":"1690_CR191","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1541-7786.mcr-23-0386","volume":"22","author":"S Tabata","year":"2024","unstructured":"Tabata S, et al. Metabolic hallmarks for purine nucleotide biosynthesis in small cell lung carcinoma. Mol Cancer Res MCR. 2024;22:82\u201393. https:\/\/doi.org\/10.1158\/1541-7786.mcr-23-0386.","journal-title":"Mol Cancer Res MCR"},{"key":"1690_CR192","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw7852","author":"L Li","year":"2019","unstructured":"Li L, et al. Identification of DHODH as a therapeutic target in small cell lung cancer. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aaw7852.","journal-title":"Sci Transl Med"},{"key":"1690_CR193","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040788","author":"WH Gmeiner","year":"2020","unstructured":"Gmeiner WH, et al. Dysregulated pyrimidine biosynthesis contributes to 5-FU resistance in SCLC patient-derived organoids but response to a novel polymeric fluoropyrimidine, CF10. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12040788.","journal-title":"Cancers"},{"key":"1690_CR194","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nrc.2016.81","volume":"16","author":"M Yang","year":"2016","unstructured":"Yang M, Vousden KH. Serine and one-carbon metabolism in cancer. Nat Rev Cancer. 2016;16:650\u201362. https:\/\/doi.org\/10.1038\/nrc.2016.81.","journal-title":"Nat Rev Cancer"},{"key":"1690_CR195","doi-asserted-by":"publisher","first-page":"104471","DOI":"10.1016\/j.isci.2022.104471","volume":"25","author":"W Shen","year":"2022","unstructured":"Shen W, et al. NRBF2 regulates the chemoresistance of small cell lung cancer by interacting with the P62 protein in the autophagy process. iScience. 2022;25:104471. https:\/\/doi.org\/10.1016\/j.isci.2022.104471.","journal-title":"iScience"},{"key":"1690_CR196","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.7150\/thno.42478","volume":"10","author":"W Shen","year":"2020","unstructured":"Shen W, et al. SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy. Theranostics. 2020;10:4466\u201380. https:\/\/doi.org\/10.7150\/thno.42478.","journal-title":"Theranostics"},{"key":"1690_CR197","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s43018-022-00358-1","volume":"3","author":"C Guo","year":"2022","unstructured":"Guo C, et al. Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer. Nat Cancer. 2022;3:614\u201328. https:\/\/doi.org\/10.1038\/s43018-022-00358-1.","journal-title":"Nat Cancer"},{"key":"1690_CR198","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1038\/s41556-018-0235-8","volume":"20","author":"AM Leidal","year":"2018","unstructured":"Leidal AM, Levine B, Debnath J. Autophagy and the cell biology of age-related disease. Nat Cell Biol. 2018;20:1338\u201348. https:\/\/doi.org\/10.1038\/s41556-018-0235-8.","journal-title":"Nat Cell Biol"},{"key":"1690_CR199","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1172\/JCI73941","volume":"125","author":"E White","year":"2015","unstructured":"White E. The role for autophagy in cancer. J Clin Investig. 2015;125:42\u20136.","journal-title":"J Clin Investig"},{"key":"1690_CR200","doi-asserted-by":"publisher","first-page":"109415","DOI":"10.1016\/j.biopha.2019.109415","volume":"119","author":"X Li","year":"2019","unstructured":"Li X, et al. Autophagy: a novel mechanism of chemoresistance in cancers. Biomed Pharmacother. 2019;119:109415. https:\/\/doi.org\/10.1016\/j.biopha.2019.109415.","journal-title":"Biomed Pharmacother"},{"key":"1690_CR201","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/em.21762","volume":"54","author":"SM Langevin","year":"2013","unstructured":"Langevin SM, Kelsey KT. The fate is not always written in the genes: epigenomics in epidemiologic studies. Environ Mol Mutagen. 2013;54:533\u201341. https:\/\/doi.org\/10.1002\/em.21762.","journal-title":"Environ Mol Mutagen"},{"key":"1690_CR202","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.semcancer.2017.09.005","volume":"51","author":"M Duruisseaux","year":"2018","unstructured":"Duruisseaux M, Esteller M. Lung cancer epigenetics: from knowledge to applications. Semin Cancer Biol. 2018;51:116\u201328. https:\/\/doi.org\/10.1016\/j.semcancer.2017.09.005.","journal-title":"Semin Cancer Biol"},{"key":"1690_CR203","doi-asserted-by":"publisher","first-page":"8107318","DOI":"10.1155\/2019\/8107318","volume":"2019","author":"YX Shi","year":"2019","unstructured":"Shi YX, Sheng DQ, Cheng L, Song XY. Current landscape of epigenetics in lung cancer: focus on the mechanism and application. J Oncol. 2019;2019:8107318. https:\/\/doi.org\/10.1155\/2019\/8107318.","journal-title":"J Oncol"},{"key":"1690_CR204","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ccell.2020.02.004","volume":"37","author":"H Huang","year":"2020","unstructured":"Huang H, Weng H, Chen J. m(6)A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell. 2020;37:270\u201388. https:\/\/doi.org\/10.1016\/j.ccell.2020.02.004.","journal-title":"Cancer Cell"},{"key":"1690_CR205","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13045-021-01173-4","volume":"14","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, et al. m(6)A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer. J Hematol Oncol. 2021;14:190. https:\/\/doi.org\/10.1186\/s13045-021-01173-4.","journal-title":"J Hematol Oncol"},{"key":"1690_CR206","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41422-018-0040-8","volume":"28","author":"Y Yang","year":"2018","unstructured":"Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m(6)A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28:616\u201324. https:\/\/doi.org\/10.1038\/s41422-018-0040-8.","journal-title":"Cell Res"},{"key":"1690_CR207","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1080\/21655979.2022.2025701","volume":"13","author":"H Kong","year":"2022","unstructured":"Kong H, Sun J, Zhang W, Zhang H, Li H. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3. Bioengineered. 2022;13:3108\u201321. https:\/\/doi.org\/10.1080\/21655979.2022.2025701.","journal-title":"Bioengineered"},{"key":"1690_CR208","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019103181","volume":"39","author":"Z Lin","year":"2020","unstructured":"Lin Z, et al. RNA m(6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 2020;39: e103181. https:\/\/doi.org\/10.15252\/embj.2019103181.","journal-title":"EMBO J"},{"key":"1690_CR209","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13046-023-02638-9","volume":"42","author":"Y Sun","year":"2023","unstructured":"Sun Y, et al. METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy. J Exp Clin Cancer Res CR. 2023;42:65. https:\/\/doi.org\/10.1186\/s13046-023-02638-9.","journal-title":"J Exp Clin Cancer Res CR"},{"key":"1690_CR210","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102768","volume":"128","author":"D Scattolin","year":"2024","unstructured":"Scattolin D, et al. The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: focus on small cell lung cancer. Cancer Treat Rev. 2024;128: 102768. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102768.","journal-title":"Cancer Treat Rev"},{"key":"1690_CR211","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.18632\/oncotarget.6413","volume":"7","author":"V Nogales","year":"2016","unstructured":"Nogales V, et al. Epigenetic inactivation of the putative DNA\/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget. 2016;7:3084\u201397. https:\/\/doi.org\/10.18632\/oncotarget.6413.","journal-title":"Oncotarget"},{"key":"1690_CR212","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13148-020-00876-8","volume":"12","author":"J Krushkal","year":"2020","unstructured":"Krushkal J, et al. Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets. Clin Epigenetics. 2020;12:93. https:\/\/doi.org\/10.1186\/s13148-020-00876-8.","journal-title":"Clin Epigenetics"},{"key":"1690_CR213","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/jrr\/rraa052","volume":"61","author":"G Zhai","year":"2020","unstructured":"Zhai G, et al. hTERT promoter methylation promotes small cell lung cancer progression and radiotherapy resistance. J Radiat Res. 2020;61:674\u201383. https:\/\/doi.org\/10.1093\/jrr\/rraa052.","journal-title":"J Radiat Res"},{"key":"1690_CR214","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1038\/s41388-020-1332-2","volume":"39","author":"AE Koyen","year":"2020","unstructured":"Koyen AE, et al. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair. Oncogene. 2020;39:4798\u2013813. https:\/\/doi.org\/10.1038\/s41388-020-1332-2.","journal-title":"Oncogene"},{"key":"1690_CR215","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1158\/0008-5472.can-14-3702","volume":"75","author":"L Sim\u00f3-Riudalbas","year":"2015","unstructured":"Sim\u00f3-Riudalbas L, et al. KAT6B is a tumor suppressor histone H3 lysine 23 acetyltransferase undergoing genomic loss in small cell lung cancer. Can Res. 2015;75:3936\u201345. https:\/\/doi.org\/10.1158\/0008-5472.can-14-3702.","journal-title":"Can Res"},{"key":"1690_CR216","doi-asserted-by":"publisher","first-page":"11154","DOI":"10.1074\/jbc.M109.066134","volume":"285","author":"N Vonlaufen","year":"2010","unstructured":"Vonlaufen N, Naguleswaran A, Coppens I, Sullivan WJ Jr. MYST family lysine acetyltransferase facilitates ataxia telangiectasia mutated (ATM) kinase-mediated DNA damage response in Toxoplasma gondii. J Biol Chem. 2010;285:11154\u201361. https:\/\/doi.org\/10.1074\/jbc.M109.066134.","journal-title":"J Biol Chem"},{"key":"1690_CR217","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1084\/jem.177.2.265","volume":"177","author":"NP Restifo","year":"1993","unstructured":"Restifo NP, et al. Identification of human cancers deficient in antigen processing. J Exp Med. 1993;177:265\u201372. https:\/\/doi.org\/10.1084\/jem.177.2.265.","journal-title":"J Exp Med"},{"key":"1690_CR218","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1084\/jem.161.5.1135","volume":"161","author":"A Doyle","year":"1985","unstructured":"Doyle A, et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med. 1985;161:1135\u201351. https:\/\/doi.org\/10.1084\/jem.161.5.1135.","journal-title":"J Exp Med"},{"key":"1690_CR219","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69\u201374. https:\/\/doi.org\/10.1126\/science.aaa4971.","journal-title":"Science"},{"key":"1690_CR220","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-019-0753-2","volume":"12","author":"Y Tian","year":"2019","unstructured":"Tian Y, Zhai X, Han A, Zhu H, Yu J. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. J Hematol Oncol. 2019;12:67. https:\/\/doi.org\/10.1186\/s13045-019-0753-2.","journal-title":"J Hematol Oncol"},{"key":"1690_CR221","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jtho.2019.03.028","volume":"14","author":"P Muppa","year":"2019","unstructured":"Muppa P, et al. Immune cell infiltration may be a key determinant of long-term survival in small cell lung cancer. J Thorac Oncol. 2019;14:1286\u201395. https:\/\/doi.org\/10.1016\/j.jtho.2019.03.028.","journal-title":"J Thorac Oncol"},{"key":"1690_CR222","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","volume":"7","author":"D Carvajal-Hausdorf","year":"2019","unstructured":"Carvajal-Hausdorf D, et al. Expression and clinical significance of PD-L1, B7\u2013H3, B7\u2013H4 and TILs in human small cell lung Cancer (SCLC). J Immunother Cancer. 2019;7:65. https:\/\/doi.org\/10.1186\/s40425-019-0540-1.","journal-title":"J Immunother Cancer"},{"key":"1690_CR223","doi-asserted-by":"publisher","first-page":"107418","DOI":"10.1016\/j.lungcan.2023.107418","volume":"186","author":"SV Liu","year":"2023","unstructured":"Liu SV, et al. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer. 2023;186:107418. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107418.","journal-title":"Lung Cancer"},{"key":"1690_CR224","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jtho.2020.05.008","volume":"15","author":"SA Best","year":"2020","unstructured":"Best SA, et al. Harnessing Natural killer immunity in metastatic SCLC. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2020;15:1507\u201321. https:\/\/doi.org\/10.1016\/j.jtho.2020.05.008.","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"1690_CR225","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jtho.2016.09.002","volume":"12","author":"H Yu","year":"2017","unstructured":"Yu H, et al. PD-L1 expression by two complementary diagnostic assays and mRNA in situ hybridization in small cell lung cancer. J Thorac Oncol. 2017;12:110\u201320. https:\/\/doi.org\/10.1016\/j.jtho.2016.09.002.","journal-title":"J Thorac Oncol"},{"key":"1690_CR226","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jtho.2018.01.008","volume":"13","author":"HS Kim","year":"2018","unstructured":"Kim HS, et al. Association of PD-L1 expression with tumor-infiltrating immune cells and mutation burden in high-grade neuroendocrine carcinoma of the lung. J Thorac Oncol. 2018;13:636\u201348. https:\/\/doi.org\/10.1016\/j.jtho.2018.01.008.","journal-title":"J Thorac Oncol"},{"key":"1690_CR227","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fimmu.2020.00018","volume":"11","author":"W Zhang","year":"2020","unstructured":"Zhang W, et al. Advances in anti-tumor treatments targeting the CD47\/SIRP\u03b1 Axis. Front Immunol. 2020;11:18. https:\/\/doi.org\/10.3389\/fimmu.2020.00018.","journal-title":"Front Immunol"},{"key":"1690_CR228","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/jci81603","volume":"126","author":"K Weiskopf","year":"2016","unstructured":"Weiskopf K, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Investig. 2016;126:2610\u201320. https:\/\/doi.org\/10.1172\/jci81603.","journal-title":"J Clin Investig"},{"key":"1690_CR229","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/s0169-5002(02)00072-7","volume":"37","author":"P Micke","year":"2002","unstructured":"Micke P, et al. Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer\u2013what limits limited disease? Lung Cancer. 2002;37:271\u20136. https:\/\/doi.org\/10.1016\/s0169-5002(02)00072-7.","journal-title":"Lung Cancer"},{"key":"1690_CR230","doi-asserted-by":"publisher","unstructured":"Nicholson AG, et al. The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:300\u2013311. https:\/\/doi.org\/10.1016\/j.jtho.2015.10.008.","DOI":"10.1016\/j.jtho.2015.10.008"},{"key":"1690_CR231","doi-asserted-by":"publisher","first-page":"17030","DOI":"10.1200\/jco.2006.24.18_suppl.17030","volume":"24","author":"R Williams","year":"2006","unstructured":"Williams R, Eskandari N, Kendall A. Staging of small cell lung cancer (SCLC): comparison of two criteria by survival analysis. J Clin Oncol. 2006;24:17030\u201317030. https:\/\/doi.org\/10.1200\/jco.2006.24.18_suppl.17030.","journal-title":"J Clin Oncol"},{"key":"1690_CR232","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2023.05.008","volume":"93","author":"JH Lee","year":"2023","unstructured":"Lee JH, Saxena A, Giaccone G. Advancements in small cell lung cancer. Semin Cancer Biol. 2023;93:123\u20138. https:\/\/doi.org\/10.1016\/j.semcancer.2023.05.008.","journal-title":"Semin Cancer Biol"},{"key":"1690_CR233","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1200\/jco.2015.63.8171","volume":"34","author":"CF Yang","year":"2016","unstructured":"Yang CF, et al. Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer. J Clin Oncol. 2016;34:1057\u201364. https:\/\/doi.org\/10.1200\/jco.2015.63.8171.","journal-title":"J Clin Oncol"},{"key":"1690_CR234","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/s1470-2045(17)30318-2","volume":"18","author":"C Faivre-Finn","year":"2017","unstructured":"Faivre-Finn C, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18:1116\u201325. https:\/\/doi.org\/10.1016\/s1470-2045(17)30318-2.","journal-title":"Lancet Oncol"},{"key":"1690_CR235","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1200\/jco.1985.3.11.1471","volume":"3","author":"WK Evans","year":"1985","unstructured":"Evans WK, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985;3:1471\u20137. https:\/\/doi.org\/10.1200\/jco.1985.3.11.1471.","journal-title":"J Clin Oncol"},{"key":"1690_CR236","doi-asserted-by":"publisher","first-page":"1185577","DOI":"10.3389\/fimmu.2023.1185577","volume":"14","author":"BC Wang","year":"2023","unstructured":"Wang BC, Fu C, Lin GH. The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data. Front Immunol. 2023;14:1185577. https:\/\/doi.org\/10.3389\/fimmu.2023.1185577.","journal-title":"Front Immunol"},{"key":"1690_CR237","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1097\/JTO.0b013e31824c7f4b","volume":"7","author":"TK Owonikoko","year":"2012","unstructured":"Owonikoko TK, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012;7:866\u201372. https:\/\/doi.org\/10.1097\/JTO.0b013e31824c7f4b.","journal-title":"J Thorac Oncol"},{"key":"1690_CR238","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/s0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet (London, England). 2019;394:1929\u201339. https:\/\/doi.org\/10.1016\/s0140-6736(19)32222-6.","journal-title":"Lancet (London, England)"},{"key":"1690_CR239","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.jtho.2023.09.027","volume":"18","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, et al. OA01.06 first-line chemotherapy with or without tislelizumab for extensive-stage small cell lung cancer: rationale-312 phase 3 study. J Thorac Oncol. 2023;18:S46. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.027.","journal-title":"J Thorac Oncol"},{"key":"1690_CR240","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/jco.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39:619\u201330. https:\/\/doi.org\/10.1200\/jco.20.01055.","journal-title":"J Clin Oncol"},{"key":"1690_CR241","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1078-0432.Ccr-16-1417","volume":"23","author":"BA Inman","year":"2017","unstructured":"Inman BA, Longo TA, Ramalingam S, Harrison MR. Atezolizumab: A PD-L1-blocking antibody for bladder cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:1886\u201390. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-1417.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1690_CR242","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107924","volume":"196","author":"M Reck","year":"2024","unstructured":"Reck M, et al. Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study. Lung Cancer. 2024;196: 107924. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107924.","journal-title":"Lung Cancer"},{"key":"1690_CR243","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s11523-021-00843-0","volume":"16","author":"ZT Al-Salama","year":"2021","unstructured":"Al-Salama ZT. Durvalumab: a review in extensive-stage SCLC. Target Oncol. 2021;16:857\u201364. https:\/\/doi.org\/10.1007\/s11523-021-00843-0.","journal-title":"Target Oncol"},{"key":"1690_CR244","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","volume":"19","author":"AKP Ganti","year":"2021","unstructured":"Ganti AKP, et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:1441\u201364. https:\/\/doi.org\/10.6004\/jnccn.2021.0058.","journal-title":"J Natl Compr Canc Netw"},{"key":"1690_CR245","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.21037\/jtd-23-588","volume":"15","author":"Y Zou","year":"2023","unstructured":"Zou Y, et al. Efficacy and safety of durvalumab + chemotherapy vs. atezolizumab + chemotherapy in the treatment of small-cell lung cancer: a retrospective comparative cohort study. J Thorac Dis. 2023;15:3339\u201349. https:\/\/doi.org\/10.21037\/jtd-23-588.","journal-title":"J Thorac Dis"},{"key":"1690_CR246","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12885-023-10784-8","volume":"23","author":"L Li","year":"2023","unstructured":"Li L, et al. First-line atezolizumab\/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer. BMC Cancer. 2023;23:318. https:\/\/doi.org\/10.1186\/s12885-023-10784-8.","journal-title":"BMC Cancer"},{"key":"1690_CR247","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/s1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:739\u201347. https:\/\/doi.org\/10.1016\/s1470-2045(22)00224-8.","journal-title":"Lancet Oncol"},{"key":"1690_CR248","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328:1223\u201332. https:\/\/doi.org\/10.1001\/jama.2022.16464.","journal-title":"JAMA"},{"key":"1690_CR249","doi-asserted-by":"publisher","first-page":"175883592312061","DOI":"10.1177\/17588359231206147","volume":"15","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Liu K, Zhu H, Cao H, Zhou Y. Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage small-cell lung cancer: a network meta-analysis of randomized controlled trial. Ther Adv Med Oncol. 2023;15:17588359231206148. https:\/\/doi.org\/10.1177\/17588359231206147.","journal-title":"Ther Adv Med Oncol"},{"key":"1690_CR250","doi-asserted-by":"publisher","first-page":"1156427","DOI":"10.3389\/fpubh.2023.1156427","volume":"11","author":"X Liang","year":"2023","unstructured":"Liang X, Chen X, Li H, Li Y. Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer. Front Public Health. 2023;11:1156427. https:\/\/doi.org\/10.3389\/fpubh.2023.1156427.","journal-title":"Front Public Health"},{"key":"1690_CR251","doi-asserted-by":"publisher","first-page":"1223020","DOI":"10.3389\/fimmu.2023.1223020","volume":"14","author":"G Xiang","year":"2023","unstructured":"Xiang G, et al. Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China. Front Immunol. 2023;14:1223020. https:\/\/doi.org\/10.3389\/fimmu.2023.1223020.","journal-title":"Front Immunol"},{"key":"1690_CR252","doi-asserted-by":"publisher","first-page":"107327482211112","DOI":"10.1177\/10732748221111296","volume":"29","author":"L Zhang","year":"2022","unstructured":"Zhang L, Geng Z, Hao B, Geng Q. Tislelizumab: a modified anti-tumor programmed death receptor 1 antibody. Cancer Control. 2022;29:10732748221111296. https:\/\/doi.org\/10.1177\/10732748221111296.","journal-title":"Cancer Control"},{"key":"1690_CR253","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.lungcan.2020.06.007","volume":"147","author":"Z Wang","year":"2020","unstructured":"Wang Z, et al. A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients. Lung Cancer. 2020;147:259\u201368. https:\/\/doi.org\/10.1016\/j.lungcan.2020.06.007.","journal-title":"Lung Cancer"},{"key":"1690_CR254","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam SJ. Toripalimab: first global approval. Drugs. 2019;79:573\u20138. https:\/\/doi.org\/10.1007\/s40265-019-01076-2.","journal-title":"Drugs"},{"key":"1690_CR255","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","volume":"11","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, et al. Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: the phase 3 EXTENTORCH randomized clinical trial. JAMA Oncol. 2025;11:16\u201325. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5019.","journal-title":"JAMA Oncol"},{"key":"1690_CR256","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124427","author":"O Kooshkaki","year":"2020","unstructured":"Kooshkaki O, et al. Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21124427.","journal-title":"Int J Mol Sci"},{"key":"1690_CR257","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1200\/jco.20.02212","volume":"39","author":"TK Owonikoko","year":"2021","unstructured":"Owonikoko TK, et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol. 2021;39:1349\u201359. https:\/\/doi.org\/10.1200\/jco.20.02212.","journal-title":"J Clin Oncol"},{"key":"1690_CR258","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jtho.2018.10.003","volume":"14","author":"N Ready","year":"2019","unstructured":"Ready N, et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol. 2019;14:237\u201344. https:\/\/doi.org\/10.1016\/j.jtho.2018.10.003.","journal-title":"J Thorac Oncol"},{"key":"1690_CR259","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","volume":"32","author":"DR Spigel","year":"2021","unstructured":"Spigel DR, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331(\u2606). Ann Oncol. 2021;32:631\u201341. https:\/\/doi.org\/10.1016\/j.annonc.2021.01.071.","journal-title":"Ann Oncol"},{"key":"1690_CR260","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP\/IFCT 4\u201312 STIMULI trial. Ann Oncol. 2022;33:67\u201379. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.011.","journal-title":"Ann Oncol"},{"key":"1690_CR261","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000980","author":"C Kim","year":"2020","unstructured":"Kim C, et al. Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000980.","journal-title":"J Immunother Cancer"},{"key":"1690_CR262","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","volume":"15","author":"HC Chung","year":"2020","unstructured":"Chung HC, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15:618\u201327. https:\/\/doi.org\/10.1016\/j.jtho.2019.12.109.","journal-title":"J Thorac Oncol"},{"key":"1690_CR263","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/jco.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38:2369\u201379. https:\/\/doi.org\/10.1200\/jco.20.00793.","journal-title":"J Clin Oncol"},{"key":"1690_CR264","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jtho.2019.10.001","volume":"15","author":"JW Welsh","year":"2020","unstructured":"Welsh JW, et al. Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensive-stage small cell lung cancer. J Thorac Oncol. 2020;15:266\u201373. https:\/\/doi.org\/10.1016\/j.jtho.2019.10.001.","journal-title":"J Thorac Oncol"},{"key":"1690_CR265","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.jtho.2020.08.022","volume":"15","author":"JW Welsh","year":"2020","unstructured":"Welsh JW, et al. Phase 1\/2 trial of pembrolizumab and concurrent chemoradiation therapy for limited-stage SCLC. J Thorac Oncol. 2020;15:1919\u201327. https:\/\/doi.org\/10.1016\/j.jtho.2020.08.022.","journal-title":"J Thorac Oncol"},{"key":"1690_CR266","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2020.12.045","volume":"502","author":"NE Donlon","year":"2021","unstructured":"Donlon NE, Power R, Hayes C, Reynolds JV, Lysaght J. Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Lett. 2021;502:84\u201396. https:\/\/doi.org\/10.1016\/j.canlet.2020.12.045.","journal-title":"Cancer Lett"},{"key":"1690_CR267","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.lungcan.2003.12.006","volume":"45","author":"R Stupp","year":"2004","unstructured":"Stupp R, Monnerat C, Turrisi AT 3rd, Perry MC, Leyvraz S. Small cell lung cancer: state of the art and future perspectives. Lung Cancer. 2004;45:105\u201317. https:\/\/doi.org\/10.1016\/j.lungcan.2003.12.006.","journal-title":"Lung Cancer"},{"key":"1690_CR268","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","volume":"22","author":"Y Cao","year":"2023","unstructured":"Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ophthalmology and beyond. Nat Rev Drug Discov. 2023;22:476\u201395. https:\/\/doi.org\/10.1038\/s41573-023-00671-z.","journal-title":"Nat Rev Drug Discov"},{"key":"1690_CR269","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1634\/theoncologist.2019-0391","volume":"25","author":"Y Liu","year":"2020","unstructured":"Liu Y, et al. A prospective study of apatinib in patients with extensive-stage small cell lung cancer after failure of two or more lines of chemotherapy. Oncologist. 2020;25:e833\u201342. https:\/\/doi.org\/10.1634\/theoncologist.2019-0391.","journal-title":"Oncologist"},{"key":"1690_CR270","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/s1010-7940(02)00112-4","volume":"21","author":"M Lucchi","year":"2002","unstructured":"Lucchi M, et al. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg. 2002;21:1105\u201310. https:\/\/doi.org\/10.1016\/s1010-7940(02)00112-4.","journal-title":"Eur J Cardiothorac Surg"},{"key":"1690_CR271","doi-asserted-by":"publisher","first-page":"e9259","DOI":"10.1097\/md.0000000000009259","volume":"96","author":"J Zhao","year":"2017","unstructured":"Zhao J, Zhang X, Gong C, Zhang J. Targeted therapy with apatinib in a patient with relapsed small cell lung cancer: a case report and literature review. Medicine. 2017;96:e9259. https:\/\/doi.org\/10.1097\/md.0000000000009259.","journal-title":"Medicine"},{"key":"1690_CR272","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1200\/jco.2010.29.3423","volume":"29","author":"DR Spigel","year":"2011","unstructured":"Spigel DR, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011;29:2215\u201322. https:\/\/doi.org\/10.1200\/jco.2010.29.3423.","journal-title":"J Clin Oncol"},{"key":"1690_CR273","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1200\/jco.2016.69.4844","volume":"35","author":"M Tiseo","year":"2017","unstructured":"Tiseo M, et al. Italian, multicenter, Phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol. 2017;35:1281\u20137. https:\/\/doi.org\/10.1200\/jco.2016.69.4844.","journal-title":"J Clin Oncol"},{"key":"1690_CR274","doi-asserted-by":"publisher","first-page":"8001","DOI":"10.1200\/JCO.2024.42.16_suppl.8001","volume":"42","author":"Y Ohe","year":"2024","unstructured":"Ohe Y, et al. BEAT-SC: a randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). J Clin Oncol. 2024;42:8001\u20138001. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8001.","journal-title":"J Clin Oncol"},{"key":"1690_CR275","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11:120. https:\/\/doi.org\/10.1186\/s13045-018-0664-7.","journal-title":"J Hematol Oncol"},{"key":"1690_CR276","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s11684-021-0916-8","volume":"16","author":"J Shi","year":"2022","unstructured":"Shi J, et al. Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202). Front Med. 2022;16:766\u201372. https:\/\/doi.org\/10.1007\/s11684-021-0916-8.","journal-title":"Front Med"},{"key":"1690_CR277","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1158\/2159-8290.Cd-18-0469","volume":"9","author":"X Gong","year":"2019","unstructured":"Gong X, et al. Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene. Cancer Discov. 2019;9:248\u201363. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0469.","journal-title":"Cancer Discov"},{"key":"1690_CR278","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1158\/2159-8290.Cd-18-0389","volume":"9","author":"MG Oser","year":"2019","unstructured":"Oser MG, et al. Cells lacking the RB1 tumor suppressor gene are hyperdependent on aurora B kinase for survival. Cancer Discov. 2019;9:230\u201347. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0389.","journal-title":"Cancer Discov"},{"key":"1690_CR279","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.1016\/j.jtho.2016.11.253","volume":"12","author":"T Owonikoko","year":"2017","unstructured":"Owonikoko T, et al. OA05.05 randomized phase 2 study: alisertib (MLN8237) or Placebo + Pac litaxel as second-line therapy for small-cell lung cancer (SCLC). J Thorac Oncol. 2017;12:S261\u20132. https:\/\/doi.org\/10.1016\/j.jtho.2016.11.253.","journal-title":"J Thorac Oncol"},{"key":"1690_CR280","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101282","volume":"4","author":"Y Li","year":"2023","unstructured":"Li Y, et al. Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1. Cell Rep Med. 2023;4: 101282. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101282.","journal-title":"Cell Rep Med"},{"key":"1690_CR281","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110814","volume":"39","author":"H Taniguchi","year":"2022","unstructured":"Taniguchi H, et al. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Rep. 2022;39: 110814. https:\/\/doi.org\/10.1016\/j.celrep.2022.110814.","journal-title":"Cell Rep"},{"key":"1690_CR282","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1158\/1078-0432.Ccr-17-2805","volume":"24","author":"A Lallo","year":"2018","unstructured":"Lallo A, et al. The combination of the PARP inhibitor olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24:5153\u201364. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2805.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1690_CR283","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/1878-0261.12882","volume":"15","author":"X Zhao","year":"2021","unstructured":"Zhao X, et al. Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation. Mol Oncol. 2021;15:1130\u201345. https:\/\/doi.org\/10.1002\/1878-0261.12882.","journal-title":"Mol Oncol"},{"key":"1690_CR284","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000847","author":"AY Lai","year":"2020","unstructured":"Lai AY, et al. CDK4\/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000847.","journal-title":"J Immunother Cancer"},{"key":"1690_CR285","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","volume":"30","author":"JM Weiss","year":"2019","unstructured":"Weiss JM, et al. Myelopreservation with the CDK4\/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib\/randomized phase II trial. Ann Oncol. 2019;30:1613\u201321. https:\/\/doi.org\/10.1093\/annonc\/mdz278.","journal-title":"Ann Oncol"},{"key":"1690_CR286","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cllc.2021.03.010","volume":"22","author":"J Weiss","year":"2021","unstructured":"Weiss J, et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind. Placebo-Controlled Stud Clin Lung Cancer. 2021;22:449\u201360. https:\/\/doi.org\/10.1016\/j.cllc.2021.03.010.","journal-title":"Placebo-Controlled Stud Clin Lung Cancer"},{"key":"1690_CR287","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1101\/gad.334516.119","volume":"34","author":"D Slade","year":"2020","unstructured":"Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020;34:360\u201394. https:\/\/doi.org\/10.1101\/gad.334516.119.","journal-title":"Genes Dev"},{"key":"1690_CR288","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/jco.18.00264","volume":"37","author":"TK Owonikoko","year":"2019","unstructured":"Owonikoko TK, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol. 2019;37:222\u20139. https:\/\/doi.org\/10.1200\/jco.18.00264.","journal-title":"J Clin Oncol"},{"key":"1690_CR289","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1158\/1078-0432.Ccr-16-1040","volume":"23","author":"BH Lok","year":"2017","unstructured":"Lok BH, et al. PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:523\u201335. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-1040.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1690_CR290","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.Can-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Can Res. 2012;72:5588\u201399. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-2753.","journal-title":"Can Res"},{"key":"1690_CR291","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1200\/jco.19.02745","volume":"38","author":"RT Penson","year":"2020","unstructured":"Penson RT, et al. Olaparib versus nonplatinum chemotherapy in patients with platinum-sensitive relapsed ovarian cancer and a germline BRCA1\/2 mutation (SOLO3): a randomized phase III trial. J Clin Oncol. 2020;38:1164\u201374. https:\/\/doi.org\/10.1200\/jco.19.02745.","journal-title":"J Clin Oncol"},{"key":"1690_CR292","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/ijc.28226","volume":"134","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Hunter T. Roles of Chk1 in cell biology and cancer therapy. Int J Cancer. 2014;134:1013\u201323. https:\/\/doi.org\/10.1002\/ijc.28226.","journal-title":"Int J Cancer"},{"key":"1690_CR293","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1158\/0008-5472.Can-16-3409","volume":"77","author":"T Sen","year":"2017","unstructured":"Sen T, et al. CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib. Can Res. 2017;77:3870\u201384. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-3409.","journal-title":"Can Res"},{"key":"1690_CR294","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1158\/1535-7163.Mct-14-1037","volume":"14","author":"C King","year":"2015","unstructured":"King C, et al. LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms. Mol Cancer Ther. 2015;14:2004\u201313. https:\/\/doi.org\/10.1158\/1535-7163.Mct-14-1037.","journal-title":"Mol Cancer Ther"},{"key":"1690_CR295","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1200\/jco.2015.64.5788","volume":"34","author":"D Hong","year":"2016","unstructured":"Hong D, et al. Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer. J Clin Oncol. 2016;34:1764\u201371. https:\/\/doi.org\/10.1200\/jco.2015.64.5788.","journal-title":"J Clin Oncol"},{"key":"1690_CR296","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204764","author":"U Hafeez","year":"2020","unstructured":"Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-drug conjugates for cancer therapy. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25204764.","journal-title":"Molecules"},{"key":"1690_CR297","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/s1470-2045(16)30565-4","volume":"18","author":"CM Rudin","year":"2017","unstructured":"Rudin CM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18:42\u201351. https:\/\/doi.org\/10.1016\/s1470-2045(16)30565-4.","journal-title":"Lancet Oncol"},{"key":"1690_CR298","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.jtho.2021.03.012","volume":"16","author":"ML Johnson","year":"2021","unstructured":"Johnson ML, et al. Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: results from the phase 3 MERU study. J Thorac Oncol. 2021;16:1570\u201381. https:\/\/doi.org\/10.1016\/j.jtho.2021.03.012.","journal-title":"J Thorac Oncol"},{"key":"1690_CR299","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","volume":"16","author":"F Blackhall","year":"2021","unstructured":"Blackhall F, et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-High SCLC: results from the phase 3 TAHOE study. J Thorac Oncol. 2021;16:1547\u201358. https:\/\/doi.org\/10.1016\/j.jtho.2021.02.009.","journal-title":"J Thorac Oncol"},{"key":"1690_CR300","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","volume":"43","author":"S Offner","year":"2006","unstructured":"Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol. 2006;43:763\u201371. https:\/\/doi.org\/10.1016\/j.molimm.2005.03.007.","journal-title":"Mol Immunol"},{"key":"1690_CR301","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.imbio.2008.11.014","volume":"214","author":"C Haas","year":"2009","unstructured":"Haas C, et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology. 2009;214:441\u201353. https:\/\/doi.org\/10.1016\/j.imbio.2008.11.014.","journal-title":"Immunobiology"},{"key":"1690_CR302","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389:2063\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2307980.","journal-title":"N Engl J Med"},{"key":"1690_CR303","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1158\/1078-0432.Ccr-22-0822","volume":"28","author":"C Diorio","year":"2022","unstructured":"Diorio C, et al. comprehensive serum proteome profiling of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome patients with B-Cell all receiving CAR T19. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28:3804\u201313. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-0822.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1690_CR304","doi-asserted-by":"publisher","first-page":"A728","DOI":"10.1136\/jitc-2022-SITC2022.0697","volume":"10","author":"L Byers","year":"2022","unstructured":"Byers L, et al. 697 A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed\/refractory small cell lung cancer (SCLC). J Immunother Cancer. 2022;10:A728\u2013A728. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0697.","journal-title":"J Immunother Cancer"},{"key":"1690_CR305","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.2217\/fon-2022-0196","volume":"18","author":"M Wermke","year":"2022","unstructured":"Wermke M, et al. Phase I trial of the DLL3\/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Future Oncol. 2022;18:2639\u201349. https:\/\/doi.org\/10.2217\/fon-2022-0196.","journal-title":"Future Oncol"},{"key":"1690_CR306","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1111\/1759-7714.15040","volume":"14","author":"Z Wang","year":"2023","unstructured":"Wang Z, et al. Investigation of the efficacy and feasibility of combined therapy of PD-L1-enhanced exogenous peripatetic adoptive natural killer (NK) cells in combination with antiangiogenic targeted therapy in the treatment of extensive-stage small cell lung cancer. Thoracic cancer. 2023;14:2877\u201385. https:\/\/doi.org\/10.1111\/1759-7714.15040.","journal-title":"Thoracic cancer"},{"key":"1690_CR307","doi-asserted-by":"publisher","first-page":"1389725","DOI":"10.3389\/fonc.2024.1389725","volume":"14","author":"T Liu","year":"2024","unstructured":"Liu T, et al. Long-term, 13-year survival after immune cell therapy combined with chemotherapy for extensive-stage small-cell lung cancer: a case report. Front Oncol. 2024;14:1389725. https:\/\/doi.org\/10.3389\/fonc.2024.1389725.","journal-title":"Front Oncol"},{"key":"1690_CR308","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/jlb.5ma0122-467r","volume":"112","author":"M Liu","year":"2022","unstructured":"Liu M, et al. CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo. J Leukoc Biol. 2022;112:901\u201311. https:\/\/doi.org\/10.1002\/jlb.5ma0122-467r.","journal-title":"J Leukoc Biol"},{"key":"1690_CR309","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00408-023-00648-0","volume":"201","author":"W Tian","year":"2023","unstructured":"Tian W, Zhao J, Wang W. Targeting CDH17 with chimeric antigen receptor-redirected T cells in small cell lung cancer. Lung. 2023;201:489\u201397. https:\/\/doi.org\/10.1007\/s00408-023-00648-0.","journal-title":"Lung"},{"key":"1690_CR310","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2023.11.032","volume":"187","author":"D Kirschenbaum","year":"2024","unstructured":"Kirschenbaum D, et al. Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma. Cell. 2024;187:149-165.e123. https:\/\/doi.org\/10.1016\/j.cell.2023.11.032.","journal-title":"Cell"},{"key":"1690_CR311","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.chest.2018.07.029","volume":"154","author":"A Thomas","year":"2018","unstructured":"Thomas A, Pattanayak P, Szabo E, Pinsky P. Characteristics and outcomes of small cell lung cancer detected by CT screening. Chest. 2018;154:1284\u201390. https:\/\/doi.org\/10.1016\/j.chest.2018.07.029.","journal-title":"Chest"},{"key":"1690_CR312","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.2967\/jnumed.121.263511","volume":"63","author":"AG Kunihiro","year":"2022","unstructured":"Kunihiro AG, et al. CD133 as a biomarker for an autoantibody-to-ImmunoPET paradigm for the early detection of small cell lung cancer. J Nucl Med. 2022;63:1701\u20137. https:\/\/doi.org\/10.2967\/jnumed.121.263511.","journal-title":"J Nucl Med"},{"key":"1690_CR313","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","volume":"18","author":"Q Wang","year":"2023","unstructured":"Wang Q, et al. SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection. J Thorac Oncol. 2023;18:31\u201346. https:\/\/doi.org\/10.1016\/j.jtho.2022.10.002.","journal-title":"J Thorac Oncol"},{"key":"1690_CR314","doi-asserted-by":"publisher","first-page":"409","DOI":"10.21037\/tlcr.2017.07.05","volume":"6","author":"V Foy","year":"2017","unstructured":"Foy V, Fernandez-Gutierrez F, Faivre-Finn C, Dive C, Blackhall F. The clinical utility of circulating tumour cells in patients with small cell lung cancer. Transl Lung Cancer Res. 2017;6:409\u201317. https:\/\/doi.org\/10.21037\/tlcr.2017.07.05.","journal-title":"Transl Lung Cancer Res"},{"key":"1690_CR315","doi-asserted-by":"publisher","first-page":"9006","DOI":"10.3390\/ijms23169006","volume":"23","author":"MD Shields","year":"2022","unstructured":"Shields MD, Chen K, Dutcher G, Patel I, Pellini B. Making the rounds: exploring the role of circulating tumor DNA (ctDNA) in non-small cell lung cancer. Int J Mol Sci. 2022;23:9006. https:\/\/doi.org\/10.3390\/ijms23169006.","journal-title":"Int J Mol Sci"},{"key":"1690_CR316","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jtho.2019.10.007","volume":"15","author":"S Mohan","year":"2020","unstructured":"Mohan S, et al. Profiling of circulating free DNA using targeted and genome-wide sequencing in patients with SCLC. J Thorac Oncol. 2020;15:216\u201330. https:\/\/doi.org\/10.1016\/j.jtho.2019.10.007.","journal-title":"J Thorac Oncol"},{"key":"1690_CR317","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1038\/s41591-023-02605-z","volume":"29","author":"SC Baca","year":"2023","unstructured":"Baca SC, et al. Liquid biopsy epigenomic profiling for cancer subtyping. Nat Med. 2023;29:2737\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02605-z.","journal-title":"Nat Med"},{"key":"1690_CR318","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s43018-022-00415-9","volume":"3","author":"F Chemi","year":"2022","unstructured":"Chemi F, et al. cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nat Cancer. 2022;3:1260\u201370. https:\/\/doi.org\/10.1038\/s43018-022-00415-9.","journal-title":"Nat Cancer"},{"key":"1690_CR319","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","volume":"25","author":"E Missiaglia","year":"2014","unstructured":"Missiaglia E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol Off J Eur Soc Med Oncol. 2014;25:1995\u20132001. https:\/\/doi.org\/10.1093\/annonc\/mdu275.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1690_CR320","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ebiom.2016.06.032","volume":"10","author":"L Fernandez-Cuesta","year":"2016","unstructured":"Fernandez-Cuesta L, et al. Identification of circulating tumor DNA for the early detection of small-cell lung cancer. EBioMedicine. 2016;10:117\u201323. https:\/\/doi.org\/10.1016\/j.ebiom.2016.06.032.","journal-title":"EBioMedicine"},{"key":"1690_CR321","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/jamaoncol.2020.0001","volume":"6","author":"T Fehlmann","year":"2020","unstructured":"Fehlmann T, et al. Evaluating the use of circulating MicroRNA profiles for lung cancer detection in symptomatic patients. JAMA Oncol. 2020;6:714\u201323. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0001.","journal-title":"JAMA Oncol"},{"key":"1690_CR322","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3233\/CBM-160254","volume":"18","author":"Y Yu","year":"2017","unstructured":"Yu Y, et al. Plasma miR-92a-2 as a biomarker for small cell lung cancer. Cancer Biomark. 2017;18:319\u201327. https:\/\/doi.org\/10.3233\/CBM-160254.","journal-title":"Cancer Biomark"},{"key":"1690_CR323","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.annonc.2022.01.008","volume":"33","author":"U Pastorino","year":"2022","unstructured":"Pastorino U, et al. Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial. Ann Oncol. 2022;33:395\u2013405. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.008.","journal-title":"Ann Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01690-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01690-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01690-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:22:53Z","timestamp":1743484973000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01690-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":323,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1690"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01690-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}